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Breast cancer is the most common malignancy among women worldwide. Over the last
four decades, diagnostic and therapeutic procedures have improved substantially, giving
patients with localized disease a better chance of cure, and those with more advanced
cancer, longer periods of disease control and survival. However, understanding and
managing heterogeneity in the clinical response exhibited by patients remains a challenge.
For some treatments, biomarkers are available to inform therapeutic options, assess
pathological response and predict clinical outcomes. Nevertheless, some measurements
are not employed universally and lack sensitivity and specificity, which might be influenced
by tissue-specific alterations associated with aging and lifestyle. The first part of this article
summarizes available and emerging biomarkers for clinical use, such as measurements
that can be made in tumor biopsies or blood samples, including so-called liquid biopsies.
The second part of this article outlines underappreciated factors that could influence the
interpretation of these clinical measurements and affect treatment outcomes. For
example, it has been shown that both adiposity and physical activity can modify the
characteristics of tumors and surrounding tissues. In addition, evidence shows that
inflammaging and immunosenescence interact with treatment and clinical outcomes
and could be considered prognostic and predictive factors independently. In summary,
changes to blood and tissues that reflect aging and patient characteristics, including
lifestyle, are not commonly considered clinically or in research, either for practical
reasons or because the supporting evidence base is developing. Thus, an aim of this
article is to encourage an integrative phenomic approach in oncology research and
clinical management.
Keywords: breast cancer, tumors, clinical response, biomarkers, immunosenescence, lifestyle, exercise,
physical activityorg February 2021 | Volume 11 | Article 6161881
1It should be considered that unless the relationship between a biomarker and
disease is causal, then a change to biomarker concentration might not necessarily
reflect a prognostic (or predictive) change.
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Breast cancer is the most common form of cancer affecting
women worldwide, with around two million new cases each
year (1). Breast cancer is the second most common form of
cancer overall and the fifth most common cause of cancer-
specific death (2). Men diagnosed with breast cancer account
for 1% of all malignancies and represent 1% of all cases
of breast cancer worldwide (3). The risk of developing breast
cancer is influenced by many factors, including age, age at
first birth, parity, breast feeding, menopausal status, physical
activity level, body composition, and hereditary factors (e.g.,
mutations in key genes, such as BRCA1) (4). Treatment
for breast cancer has improved over the last four decades
and can consist of a combination of traditional and more
advanced interventions including surgery, chemotherapy,
radiation therapy, hormone therapy, small molecule therapy,
immunotherapy and other targeted approaches (such as mTOR
inhibitors) (5). Although most treatments are very effective, the
clinical profile and characteristics of each patient are unique and
tumor heterogeneity—even among patients with the same TNM
(T: tumor, N: node, M: metastasis) staging—results in patient-to-
patient variation in clinical outcomes. This patient-to-patient
variation in clinical outcomes might partly be due to genetic
factors, including germline mutations (e.g., BRCA1/2 or P53) or
polymorphisms in genes encoding drug metabolizing enzymes
and transporters (e.g., DPYD, TPMT or UGT1A1, involved in
5-fluorouracil, mercaptopurine or irinotecan metabolism,
respectively) (6–8). Although these factors can be assessed, a
challenge that remains is predicting which patients will
respond optimally to different treatment options, and to
stratify patients to provide the best care (9). Difficulties in
managing heterogeneity in the clinical response exhibited
by patients emphasizes the need to consider other factors
when measuring and interpreting predictive and prognostic
biomarkers in breast cancer.
Biomarkers are molecular, histological, radiographical or
physiological characteristics that can be measured as an
indicator of normal biological processes, pathogenic processes,
or responses to an exposure or intervention, including therapy
(10). From a clinical perspective, a biomarker could be described
as an objective observation of the medical state of a patient,
which can be assessed accurately and reproducibly (11). To be
reliable, biomarkers need to be sensitive and specific. Sensitivity
refers to the ability of the biomarker to correctly identify patients
with a disease from the whole population, and specificity refers to
the ability of the biomarker to correctly identify people without
the disease (12, 13). Molecules linked with the presence of cancer
are often referred to as tumor biomarkers or tumor antigens,
where antigens are molecules containing sites that are recognized
by, and interact with, components of the immune system.
Neoantigens are antigens that are generated by somatic
mutations in the tumor, whereas tumor-associated antigens
can also be found in healthy tissues, usually at lower levels
(14). Many classical tumor biomarkers are proteins, and they can
either be located on the cell surface, in the intracellular space or
secreted into body fluids by cancer cells or other local cells inFrontiers in Immunology | www.frontiersin.org 2response to the tumor(s) (2, 15). Further, many tumor
biomarkers are shared among different cancers with only a few
biomarkers being disease specific (2).
Tumor biomarkers can be categorized based on their role and
time of assessment, including diagnostic, monitoring, predictive
or prognostic biomarkers (16, 17). Diagnostic biomarkers, for
example, show utility in early phases of disease, as they confirm
the presence of a tumor, whereas biomarkers used for
monitoring disease become more relevant following diagnosis
and during treatment, as their serial measurement gives real-time
information of disease status (16). In this review, our focus is
largely on predictive and prognostic biomarkers, given their
utility in establishing the clinical response to treatment.
Predictive biomarkers assess the response or lack of response
to a specific form of therapy, while prognostic biomarkers can
reflect the natural course of the disease and thus can assess
clinical outcomes in the absence of therapy (18). When
interpreting any type of biomarker, the specific endpoint of
analysis should also be taken into consideration (19). Examples
include calculations of progression-free survival or objective
response rates. The increasing relevance of biomarkers in the
management of cancer has led to the development of a number
of agencies who support and advise on the clinical use of
biomarkers, including the American Society of Clinical
Oncology (ASCO) (20–24), the American National Academy
of Clinical Biochemistry (NACB) (25), the European Group of
tumor markers (EGTM) (5, 26), the European Society of Medical
Oncology (ESMO) (27, 28), the National Institute for Health and
Care Excellence (NICE) and the National Comprehensive
Cancer Network (NCCN). Guidelines have also been produced
with the validation steps needed for biomarkers to reach the
clinics, including evaluation of confounding factors, analytical
and clinical validation, demonstration of clinical utility and
regulatory approval (29). Further, a biomarker registry has
been created to compile data from ongoing, completed but not
yet published, and completed studies, as well as those with
negative results, serving as a useful tool for further analyses or
for the design of new biomarker studies (30).
The search for new cancer biomarkers continues, and once
measurements become established, there is often further
validation and refinement, including the assessment of other
biomarkers simultaneously, to improve the sensitivity or
specificity of tests. An additional step, often not undertaken
either for practical reasons or because the supporting evidence
base is developing, is understanding whether cancer biomarkers
are influenced by broader factors, including the characteristics of
patients and their lifestyle. If it could be established, that factors
such as age, physical activity level, or body composition,
influence the concentration or characteristics of a given
biomarker, then accounting for these inter-individual patient-
centric factors, might improve the clinical utility of that
measurement1. Given that first; some biomarkers indicate the
severity of disease and are secreted or expressed by tumor cellsFebruary 2021 | Volume 11 | Article 616188
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exercise, physical activity or body composition, are known to
influence disease progression (35–40), then it is conceivable that
there is interaction. Indeed, the effects of age, exercise, and
adiposity, on the composition and function of cells, tissues and
organs, is well established, and there are a variety of mechanistic
links with disease (41, 42). In turn, the composition and
characteristics of tissues that are both local and distant to
tumor sites, could influence the measurement of cancer
biomarkers and also disease progression directly.
The first part of this article summarizes current and emerging
breast cancer biomarkers that are measured in tumors or in
blood (see Tables 1A, 1B and Table 2). The second part of this
article summarizes the effects that aging, exercise or physical
activity, and adiposity can have, on the cellular composition and
function of a variety of cells and tissues, including tumors. In
places, links between these broader characteristics of patients and
overall cancer risk, disease progression, and treatment outcomes
are highlighted. In summary, the overall aim of this article is to
encourage an integrative phenomic approach in oncology
research and clinical management.MEASUREMENTS IN TUMORS
Estrogen Receptor (ER)
Estrogen receptors (ERs) are nuclear steroid receptors that
operate as transcriptional regulators of several cell processes,
such as proliferation and differentiation, in response, primarily,
to estrogen (45). There are two forms, ER-alfa and ER-beta, and
the majority of ER-positive tumors express the alfa form (49,
120). ER expression is measured by semiquantitative
immunohistochemistry in formalin-fixed paraffin-embedded
tumor biopsies (46). ER expression has proven importance as a
prognostic and predictive factor by identifying which patients
will respond to hormone therapies (e.g., aromatase inhibitors,
tamoxifen and other ER antagonists) informing treatment
decisions, and providing an estimate of overall survival (2). For
almost 50 years, many studies have confirmed both the
prognostic and the predictive value of ER measurements (31,
43) and ER status is used widely in clinics after diagnosis. For
example, a study analyzed data from 4478 breast cancer patients
across seventeen cancer registries in six European countries, to
determine the influence of hormone receptor status on survival
(121). Comparing ER status and relative survival over 5 years, it
was found that women who had been classified as ER positive
had better outcomes (90% survival, 95% CI: 88–92) compared to
ER-negative counterparts (77% survival; 95% CI: 73–78). Among
ER-positive women, tamoxifen treatment was associated with a
10% decrease in relative excess risk of death compared to women
not treated with tamoxifen. Although the majority of studies
examining ER have focused on the alfa form, some reports have
shown prognostic value of the beta isoform, even in ER-alpha
negative tumors (44, 122). Attention has been directed more
recently to mutations in the gene that encodes the ER—so called
ESR1 mutations—because they have been associated withFrontiers in Immunology | www.frontiersin.org 3resistance to endocrine therapy, especially in metastatic
settings (62).
Progesterone Receptor (PR)
Progesterone receptors (PRs) are also nuclear steroid receptors
that govern processes such as proliferation and differentiation
in response, primarily, to progesterone. There are two
isoforms, PR-alpha and PR-beta, which regulate different
genes (50). PR expression is measured by semiquantitative
immunohistochemistry in formalin-fixed paraffin-embedded
tumor biopsies. In healthy breast tissue, both isoforms
are expressed equally, but some studies have shown a
dysregulation of this balance in breast cancer (47). A large
literature base supports the use of PR status for predicting
clinical outcomes. For example, a study defined both clinical
utility and cut off points of immunohistochemistry for PR status
measurement in a ‘test’ group of 1235 cases of primary breast
cancer receiving endocrine therapy. This study then confirmed
clinical utility for successful therapeutic outcomes in an extra
‘validation’ group of 423 breast cancer patients who underwent
mastectomy and were randomized to either 5 years of adjuvant
tamoxifen treatment or no adjuvant treatment (123). Analysis of
formalin-fixed samples from the 423 patients showed that PR
was a strong and significant predictive factor of both improved
disease-free and overall survival (HR = 0.546, P = 0.0034; HR =
0.595, P = 0.0040 respectively). The PR-alpha/PR-beta ratio has
also been suggested to influence responsiveness to hormone
therapies, with some studies showing that a high ratio of PR-
alpha to PR-beta expression is linked to tamoxifen resistance
(48). Combined with information from assessing ER-status, it is
known that tumors expressing both ER and PR respond best to
endocrine therapies (49).
Human Epidermal Growth Factor
Receptor 2 (HER2)
Human epidermal growth factor receptor 2 (HER2; also known
as c-erbB-2, due to the encoding gene, or HER2/neu, due to its
discovery in neuroblastoma rat models (51)), is an epithelial
growth factor oncoprotein, localized in the cell membrane and
involved in communication among cells for proliferation,
differentiation and survival signalling (2). HER2 is commonly
measured in formalin fixed sections of tumor tissue, by
immunohistochemistry, but also by Fluorescence In Situ
Hybridization (56). HER2 status is most commonly used to
identify patients eligible for treatment with HER2-targetting
therapies such as trastuzumab, also known as herceptin (22,
52). HER2 status has prognostic and predictive value, in part, due
to the effectiveness of HER2-targetting therapies. However,
HER2 positivity and overexpression has been associated with
worse prognosis and reduced disease-free and overall survival in
the absence of HER2-targetting treatments (124). In addition,
HER2 expression has been associated with resistance to
endocrine therapy, especially tamoxifen (53, 57, 125, 126) but
has been linked with the success of other chemotherapy
regimens. For example, a study including 638 patients with ER
and/or PR negative tumors and axillary lymph nodeFebruary 2021 | Volume 11 | Article 616188
Arana Echarri et al. Aging, Lifestyle and Breast CancerTABLE 1A | Measurements made in tumours: singleplex/duplex/quadruplex assays.
Biomarker
or test








ER Singleplex Semiquantitative IHC, FFPE (31, 43–44) (2, 45, 46) ASCO (20): treatment decisions
EGTM (26): treatment decisions
ESMO (27, 28): treatment decisions
NACB (25): treatment decisions; prognosis
(combined biomarkers)
Yes
PR Singleplex IHC, FFPE (47–48) (49, 50) ASCO (20): treatment decisions
EGTM (26): treatment decisions
ESMO (27, 28): treatment decisions
NACB (25): treatment decisions; prognosis
(combined biomarkers)
Yes
HER2 Singleplex IHC, FISH, sequencing; FFPE (51, 52–53–55) (56, 57) ASCO (20): treatment decisions
EGTM (26): treatment decisions
ESMO (27, 28): treatment decisions






Duplex ELISA, fresh/frozen tissue, FFPE (32, 58–59) (60, 61) ASCO (20): prognosis newly diagnosed (node−)
ASCO (62): treatment decisions (adjuvant therapy
ER+HER2−node−)
EGTM (26): prognosis (combined biomarkers);
prediction (adjuvant therapy ER+HER2−node−)
ESMO (27, 28): prognosis (node−/+); treatment
decisions (combined biomarkers; early disease)
NACB (25): prognosis; further evaluation for
treatment decisions
Note (A)
P53 Singleplex IHC, TTGE/sequencing, cDNA
microarrays; FFPE
(63, 64–65) (66, 67) ASCO (20, 22): insufficient data for treatment
decisions
EGTM (5): insufficient data
ESMO (27, 28): not mentioned
NACB (25): prognosis (conflicting results)
2007 3rd international workshop on TP53:
prognosis
No
Ki-67 Singleplex IHC, RT qPCR
fresh/frozen tissue, FFPE
(68–69) (70, 71) ASCO (20): insufficient data for prognosis
ASCO (62): not recommended for treatment
decisions
EGTM (26): prognosis if combined
ESMO (28): prognosis ER+HER2−, treatment
decisions (combined biomarkers; adjuvant
therapy)
NACB (25): not mentioned





Singleplex IHC (FFPE); immunoenzymatic or
radiometric assays (tumour
lysates); Western Blotting
(73–74) (75, 76) ASCO (20): insufficient data for prognosis/
prediction
EGTM (5): insufficient data
ESMO (27, 28): not mentioned
NACB (25): prognostic (node−; conflicting results)
No
PSA Singleplex IHC (FFPE), ELISA (tumour
cytosolic extracts)
117 (77–78) ASCO (20, 22): not mentioned for BC
EGTM (5, 26): Not mentioned for BC
ESMO (27, 28): Not mentioned for BC





IHC, FFPE (79, 80) ASCO (22): Not recommended for treatment
decisions
EGTM (5, 26): not mentioned
ESMO (27, 28): not mentioned
NACB (25): not mentioned
2018 NICE DG34 guidelines: not recommended
for treatment decisions in early ER+HER2-node-
(uncertain analytical validity)Frontiers in Immunology | www.frontiersin.org 4 February 2021 | Volume 11 | Article 616188
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Biomarker
or test







TILs Multiplex Microscopy, ICC, flow
cytometry, gene expression;
blood, fresh/frozen tissue, FFPE
(81–82) ASCO (22): insufficient evidence for treatment
decisions
EGTM (5, 26): not mentioned
ESMO (28): prognosis, not treatment decisions
NACB (25): not mentioned
2014 International TILs working group (83):
guidelines/recommendations







RT PCR, FFPE (84–85) ASCO (20, 22): prognosis/prediction (adjuvant
therapy, tamoxifen)
EGTM (26): prognosis/prediction (adjuvant
therapy, tamoxifen ER+HER2−
ESMO (28): prognosis/prediction (adjuvant
therapy; combined biomarkers)
NACB (25): prognosis/prediction (adjuvant
therapy; combined biomarkers)
2018 NICE DG34 guidelines: treatment decisions







(86–87) ASCO (23): prognosis/treatment decisions
EGTM (26): prognosis/treatment decisions
(adjuvant therapy; invasive)
ESMO (28): prognosis/prediction adjuvant
therapy; combined biomarkers)
NACB (25): not mentioned
2018 NICE DG34 guidelines: not recommended







Microarray, FFPE (88–89) ASCO (22): treatment decisions (adjuvant therapy,
combined biomarkers, ER+HER2−node−)
EGTM (26): prognosis/ treatment decisions
(adjuvant therapy, combined biomarkers, ER+
HER2−)
ESMO (28): prognosis/prediction (adjuvant
therapy, combined biomarkers)
NACB (25): not mentioned
2018 NICE DG34 guidelines: treatment decisions






RT PCR, FFPE (90–91) ASCO (22): treatment decisions (adjuvant therapy
ER+HER2−node−)
EGTM (26): prognosis/treatment decisions
(adjuvant therapy, combined biomarkers, ER+
HER2−)
ESMO (28): prognosis/prediction (adjuvant
therapy, combined biomarkers)
NACB (25): not mentioned
2018 NICE DG34 guidelines: treatment decisions
in early ER+HER2-node- (adjuvant chemotherapy)








Microarray, fresh/frozen tissue (92–93) ASCO (20): insufficient data
EGTM (26): insufficient data
ESMO (28): not mentioned
NACB (25): not mentioned
Not commercially available
No
ASCO: American Association of Clinical Oncology; BC: Breast Cancer; Chemo: chemotherapy; EGTM: European Group of Tumour Markers; ELISA: Enzyme Linked Immunosorbent
Assay; ER: Estrogen receptor; FDA: Food and Drug Administration; ESMO: European Society of Medical Oncology; FISH: Fluorescence In Situ Hybridization; FFPE: formalin-fixed paraffin-
embedded tissue; HER2: Human Epidermal Growth Factor Receptor 2; ICC: Immunocytochemistry; IHC: Immunohistrochemistry; NACB: American National Academy of Clinical
Biochemistry; NICE: National Institute for Health and Care Excellence; PR: Progesterone receptor; PSA: Prostate Specific Antigen; RT PCR: reverse transcription Polymerase Chain
Reaction; RT qPCR: Quantitative reverse transcription Polymerase Chain Reaction; TILs: Tumour Infiltrating Lymphocytes; TTGE: temporal temperature gradient gel electrophoresis; UPA
and PAI: Urokinase plasminogen activator and Plasminogen Activator Inhibitor 1. Notes: (A) Not widely used as fresh or freshly frozen tissue is required.Frontiers in Immunology | www.frontiersin.org 5 February 2021 | Volume 11 | Article 616188
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benefited from chemotherapeutic regimens where anthracycline-
based drugs such as doxorubicin were added, compared to HER2
negative patients. The 10-year disease free survival of HER2
positive patients increased from 26% to 41% when treated
with doxorubicin, whereas survival did not change in the
HER2 negative group (40 vs. 41%) (54). In another study, 442
women with node positive breast cancer were randomized to
three different doses of adjuvant chemotherapy, combining
cyclophosphamide, doxorubicin and fluorouracil. Women with
tumors overexpressing HER2 (≥50% overexpression) benefited
the most from high doses of chemotherapy, compared to those
with little or no expression of HER2 (55).
Urokinase Plasminogen Activator (uPA) and
Plasminogen Activator Inhibitor 1 (PAI-1)
Urokinase plasminogen activator (uPA) is a serine protease that
converts plasminogen into plasmin, which has a key role in
degradation of extracellular matrix-components, leading to
release of growth factors implicated in migration and invasion
(60, 61). The proteolytic activity of uPA is regulated by inhibitors
such as plasminogen activator inhibitor 1 (PAI-1). Given the role
of uPA in metastasis, PAI-1 was once thought to be protective,
but studies have shown that this inhibitor is also associated with
tumorigenesis, likely by preventing apoptosis (58) or enhancing
angiogenesis (32). Simultaneous measurement of both molecules
has been shown to have better prognostic and predictive value
compared to measuring them separately (127). Both uPA and
PAI-1 are commonly measured in parallel with enzyme-linked
immunosorbent assays (ELISA) in extracts of the primary tumor,
and general reference cut off levels are 3 ng/mg and 14 ng/mg
respectively. uPA and PA-1 levels have prognostic value in breast
cancer patients regardless of menopausal status (128) and node
status (129, 130), and high levels of both markers have been
significantly associated with shorter overall and disease-free
survival. A prospective randomized control trial showed that
uPA and PAI-1 levels also had predictive value, identifying
lymph-node negative breast cancers with better responses to
adjuvant chemotherapy consisting of cyclophospamide,
methotrexate and 5-fluorouracil (CMF) (131). In this study,
breast cancer patients were stratified into either a high-risk or
low-risk group, depending on whether they had high or low
levels of uPA and PAI-1, respectively. Among the high-risk
group, patients receiving chemotherapy had a 44% decrease in
the relative risk of disease recurrence compared to those who did
not receive treatment (RR = 0.56, 95% CI: 0.25–1.28). Similar
findings have been reported in other studies (59), and future
studies need to confirm clinical utility with other more
commonly used treatment regimens (132).
Tumor Protein 53 (P53)
Tumor protein P53 is a nuclear protein involved in cell cycle
regulation that also acts as a tumor suppressor, binding to DNA
in the presence of damage and triggering either DNA repair
pathways, checkpoint arrest or apoptosis (66). In tumors, one or
both alleles of P53 are commonly deleted and/or mutated (63),Frontiers in Immunology | www.frontiersin.org 6and this can result in non-functional P53, which, unable to detect
DNA damage, contributes to tumorigenesis. Overexpression of
mutated versions of P53 can promote tumor formation due to
oncogenic gain-of-function activity (67). Traditionally P53 status
is examined by immunohistochemistry in formalin fixed paraffin
blocks, which is useful for identifying overexpression. However,
given the importance of identifying specific mutations, Temporal
Temperature Gradient Gel Electrophoresis, with sequencing of
aberrant migrating bands to determine the nature of mutations, or
cDNA microarrays are now more common. Overexpression of
P53 protein and some mutations have been linked with poor
prognosis and shorter survival (64, 133–137). For example, there
was a significant reduction in disease free survival over 5 years
among 700 women with node-negative breast cancer exhibiting
tumors that were positive for a mutated version of P53. Disease
free survival probability at 5 years was 80% for P53 negative
tumors, 72% for P53 positive tumors with low expression, and
58% for P53 positive tumors with high expression (P < 0.05) (133).
Some studies have supported the predictive value of P53 for
treatment outcomes, as certain mutations (e.g., stop codons,
point or deletion mutations, in regions like the zinc-binding
domain) have been associated with resistance to some forms of
chemotherapy (e.g., doxorubicin, tamoxifen, 5-fluorouracil and
mitomycin, or cyclophosphamide, methotrexate and 5-florouracil)
or radiotherapy (138–144). Other studies on the other hand, have
shown better responses to certain chemotherapy regimens (e.g.
paclitaxel, or epirubicin and cyclophosphamide) among patients
with mutations in P53, such as deletions, transversions or
transitions in exons 4, 6, 8 or 10 (65, 145).
Ki-67
Ki-67 is a nucleic protein that is a marker of proliferation
expressed at higher levels during mitosis (70). It is commonly
assessed by immunohistochemistry, typically using the MIB-1
antibody (71), although examining gene expression using RT
qPCR provides comparable results (68). High Ki-67 expression
in tumor tissue is associated with poorer outcomes (146–149).
For example, a metanalysis of 12,155 breast cancer patients
showed that, in the overall population, Ki-67 expression was
associated with decreased overall (HR 1.95, 95% CI: 1.70–2.24;
P < 0.001) and disease-free survival (HR 1.93, 95% CI: 1.74–2.14;
P < 0.001) (146). Similar results have been shown by other
studies, examining patients undergoing endocrine therapy (150).
On the other hand, some studies have shown that positive
responses to certain forms of therapy can be predicted with
high Ki-67 scores, such as some chemotherapy combinations
(e.g., docetaxel, fluorouracil and epirubicin) in ER positive
tumors (151) or addition of adjuvant chemotherapy to
endocrine therapy in HER2 negative tumors (152). However,
other studies have not been able to prove predictive value of Ki-
67 (69, 153). The International Ki-67 in Breast cancer working
group reviewed the available evidence base and provided
guidelines for the accurate measurement of this marker (72).
D Cathepsin
D cathepsin is a lysosomal aspartyl protease that breaks down
intracellular and endocytosed proteins in most mammalian cellsFebruary 2021 | Volume 11 | Article 616188
Arana Echarri et al. Aging, Lifestyle and Breast Cancer(75) and is involved in remodeling processes in mammary tissue
(76). D cathepsin can be assessed by immunohistochemistry in
formalin fixed paraffin embedded tumor samples, or
immunoenzymatic assays and radiometric immunoassays in
breast tumor lysates or by Western Blotting. Some studies have
indicated that D cathepsin has prognostic value in primary breast
cancer. For example, in an analysis of 2810 cytosolic extracts ofFrontiers in Immunology | www.frontiersin.org 7breast tissue by radiometric immunoassay, it was shown that
tumors with high levels of D cathepsin had significantly poorer
relapse-free and overall survival regardless of node or
menopausal status (73). In addition, dividing D cathepsin
levels into four quartiles (Q1: 0–33, Q2: > 33–47, Q3: > 47–70,
and Q4: > 70 pmol/mg protein) an association was shown
between patients in the higher quartiles with early relapse andTABLE 2 | Measurements made in blood: singleplex and multiplex assays.
Biomarker
or test








(94–95) (2) ASCO (20, 21): monitor treatment (combined
biomarkers, metastatic)
EGTM (5): prognosis (combined biomarkers,
early recurrence)
ESMO (27, 28): not mentioned











(33, 96–97) ASCO (20, 21): monitor treatment (combined
biomarkers, metastatic)
EGTM (5): prognosis (combined biomarkers,
early recurrence)
ESMO (27, 28): not mentioned





(98, 99) ASCO (20, 22): Not mentioned (favor: CA15.3 &
CA 27.29)
EGTM (5): Not mentioned (favor: CA15.3 & CA
27.29)
ESMO (27, 28): not mentioned






(100, 101–102) ASCO (20, 22): insufficient evidence prognosis/
treatment
EGTM (5, 26): Not mentioned
ESMO (27, 28): Not mentioned










ASCO (20, 22): not mentioned for BC
EGTM (5, 26): Not mentioned for BC
ESMO (27, 28): Not mentioned for BC
NACB (25): not mentioned for BC
No
ctDNA Multiplex PCR or sequencing
techniques, blood
(108, 109) (107) ASCO/CAP (24): complementary to genomic
tests (metastasis), insufficient evidence (early-
stage/monitoring/recurrence)
EGTM (5, 26): not mentioned
ESMO (27, 28): not mentioned
NACB (25): not mentioned
FDA approved (PIK3CA mutation test) (110)
No
CTCs Multiplex Microscopy, flow
cytometry, RT-PCR, blood
(34, 111–112) (113) ASCO (20, 22): insufficient evidence for
treatment decisions
EGTM (5, 26): not mentioned
ESMO (27, 28): not mentioned
NACB (25): prognosis/monitoring (advanced
disease, undergoing evaluation)





Multiplex Flow cytometry, blood (115–117) (118, 119) No NoFebruary 2021 | Volume 11ASCO: American Association of Clinical Oncology; BC: Breast Cancer; CAP: College of American Pathologists; CEA: Carcinoembryonic Antigen; CTCs: Circulating Tumour Cells; ctDNA:
Circulating tumour DNA; EGTM: European Group of Tumour Markers; ELISA: Enzyme Linked Immunosorbent Assay; FDA: Food and Drug Administration; ESMO: European Society of
Medical Oncology; HER2: Human Epidermal Growth Factor Receptor 2; HE4: Human epididymis protein; MCA: Mucin-like carcinoma associated antigen; NACB: American National
Academy of Clinical Biochemistry. PSA: Prostate Specific Antigen.| Article 616188
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with highest D cathepsin levels was 36% compared to 55%
among the group with the lowest levels. In addition, overall
survival probability was 43% in the group with the highest levels
compared to the 63% in the group with the lowest levels.
Although other studies have shown similar results (154–156),
the prognostic value of D cathepsin has not been fully established
and is not used routinely. However, some studies have shown
associations with treatment outcomes, as patients with higher
levels seem to benefit from tamoxifen-based therapies (157, 158)
but other studies show no impact (74, 159).
Prostate-Specific Antigen (PSA)
Prostate-specific antigen (PSA) is a serine protease with
chymotrypsin-like activity which is normally released from
the prostate into seminal fluid to increase sperm motility. PSA
is most commonly considered to be a serum biomarker
for the diagnosis, prognosis and progression of prostate
adenocarcinomas. However, PSA is also produced by other
tissues, including the breast, and PSA has received attention in
breast cancer (103). PSA can be detected by different methods,
such as immunoassays in tumor cytosolic extracts, or
immunohistochemistry and studies have shown prognostic
value in breast cancer (77, 160). For example, a study of 174
breast cancer patients measured PSA in samples of tumor cytosol
and found that PSA positive tumors correlated with early disease
stage, smaller tumors and estrogen receptor positivity (77).
Moreover, patients with PSA-positive tumors showed a
significantly lower risk of relapse and death. However, other
studies have not been able to confirm independent prognostic
value for PSA (161, 162). Studies have also linked PSA to
treatment outcomes. For example, in an analysis of tumor
cytosol from 434 patients with breast cancer that had recurred
who were treated with tamoxifen, a significant association was
shown between high PSA and poor treatment response, as well as
poor progression-free and overall survival (P < 0.001) (78).
Further research is needed to confirm the clinical utility of
PSA in breast cancer.
IHC4
Immuno-HistoChemical-4 score (IHC4) is a four-parameter
immunohistochemistry test that measures the ER, PR, HER2
and Ki-67 in formalin fixed paraffin embedded tumor samples.
In 2011, the ATAC trial (Arimidex, Tamoxifen, Alone or in
Combination) examined the prognostic value of combining
those four immunohistochemistry markers among 1125 ER
positive breast cancer patients in comparison with another
multiparameter test—Oncotype DX, or Genomic Health
Recurrence Score—covered in the next section (79). A
prognostic model and a combined score, the IHC4 score was
computed. Results showed independent prognostic value of each
of the immunohistochemical markers, and a prognostic value for
the IHC4 score that was comparable to that of Oncotype DX
(although IHC4 score was slightly more prognostic for distant
recurrences). In turn, the IHC4 score was subsequently examined
and validated in an additional group of 786 ER positive patients.
High levels of the adjusted IHC4 score were shown to be a strongFrontiers in Immunology | www.frontiersin.org 8prognostic factor for negative outcome (HR = 4.1, 95% CI: 2.5–
6.8). Other later studies have confirmed the utility of IHC4 to
identify ER positive breast cancer patients that have a low risk of
recurrence (80). However, the IHC4 test needs further validation
and investigation in large randomized trials before it can be used
routinely in clinical practice.
Tumor Infiltrating Lymphocytes (TILs)
Tumor infiltrating lymphocytes (TILs) reflect the immune
response to the presence of a tumor (81). Most studies have
focused on the predictive value of T cells, but many other
immune cell subtypes are present within tumors, including
natural killer cells, B cells and, despite the common name
referring to “lymphocytes”, macrophages have also received
attention (163). TILs can be detected by several methods
including immunocytochemistry, flow cytometry, gene
expression and semiquantitative histological evaluation by light
microscopy (164). The frequency of TILs varies among the
different breast cancer subtypes, and TILs are typically most
abundant in the most aggressive forms, such as basal-like (ER−
PR−HER−) and HER2-positive tumors (165). Studies have
shown that infiltration of some lymphocyte sub-types, such as
cytotoxic CD8+ T cells and helper CD4+ T cells, B cells and
dendritic cells, are associated with good prognosis and therefore
longer survival. However, studies have also shown that the
infiltration of other cells, including regulatory T cells,
neutrophils, and tumor-associated macrophages (TAMs) with
an M2-like (alternatively activated) phenotype are associated
with worse prognosis (82, 164, 166–168). Studies have examined
the predictive value of TILs in the context of treatment
outcomes, showing significant associations between high
frequencies of TILs and positive responses to anthracycline-
based chemotherapy (166), or to chemotherapy combined with
trastuzumab (81). TILs have received a lot of attention in
research settings, and studies have interpreted results in a
variety of ways, including examining the presence or absence
of cell subtypes, and also their relative abundance. The
international TILs working group meeting in 2013 produced
guidelines for these assessments, yet further work is required for
routine clinical use (83).
Oncotype DX
Oncotype DX, developed by Genomic Health (California, USA;
now part of Exact Sciences, Wisconsin, USA), is a
multiparameter RT-PCR assay that simultaneously measures
the expression of 21 genes in formalin-fixed paraffin embedded
tumor samples. The panel of genes includes 16 cancer-related
genes, such as HER2 and ER, and others implicated in
proliferation and invasion, and also 5 genes for reference (84).
Based on the relative expression of each gene, a recurrence score
is computed classifying patients into three risk categories: low
(recurrence score lower than 18), intermediate (recurrence score
between 18 and 30), and high (recurrence score above 30). The
assay was designed to predict risk in lymph node negative, ER
positive breast cancer patients treated with tamoxifen. The
prognostic value of the Oncotype DX recurrence score has
been extensively validated. High scores are associated withFebruary 2021 | Volume 11 | Article 616188
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positive and lymph node negative patients (84, 85, 169–172). The
predictive value of this test is best demonstrated by identifying
patients with ER positive tumors who would benefit most from
adjuvant chemotherapy, regardless of node involvement (170,
172). A study tested the 21-gene recurrence score assay in tumor
samples from the phase III trial SWOG-8814, which included
lymph node negative ER-positive breast cancer patients treated
with either tamoxifen alone or with chemotherapy consisting of
cyclophosphamide, doxorubicin and fluorouracil prior to
tamoxifen (172). The study confirmed the significant
prognostic value of the assay in the tamoxifen alone group as
shown by previous studies. The study also showed a significant
improvement in survival from the addition of chemotherapy to
tamoxifen in the high-risk score group, but a lack of benefit from
chemotherapy in low-intermediate score groups. In the high risk
group, the 10-year estimates for percentage of disease-free
survival were 55% for chemotherapy and tamoxifen vs. 43%
for tamoxifen alone (P = 0.033), and for overall survival, 68% for
chemotherapy and tamoxifen vs. 51% for tamoxifen alone, (P =
0.027), and for breast-cancer specific survival, 73% for
chemotherapy and tamoxifen vs. 54% for tamoxifen alone (P =
0.033). On this basis, Oncotype DX and similar platforms are
routinely used to help decision-making for the use of adjuvant
chemotherapy in ER-positive breast cancer. Further research is
needed to evaluate the use of Oncotype DX among ER
negative patients.
MammaPrint
Mammaprint, developed by Agendia (Amsterdam, Netherlands),
is a multi-parameter microarray-based technique that
simultaneously measures the expression of 70 genes in either
fresh or frozen tumor tissue or formalin fixed paraffin embedded
samples, which produces a recurrence score. In turn, patients are
classified as either low risk with a good prognosis signature, or
high risk with a bad prognosis signature. Several studies have
confirmed the clinical utility of this test to identify patients with
better or worse outcome (86, 173, 174), and to inform clinical
decisions over whether to treat patients with adjuvant
chemotherapy following surgery (175, 176). One of these is the
MINDACT study (Microarray in Node- Negative Disease may
Avoid ChemoTherapy), a prospective randomized trial, which
was conducted with 6693 patients diagnosed with early breast
cancer. In this study, the recurrence risk calculated by
Mammaprint and referred to as genomic risk was compared
with risk calculated by an online decision-making tool for
clinicians that was available at the time (Adjuvant!Online;
referred to as clinical risk) (87, 176). Patients were assigned as
being low or high risk with both scores. There were 1550 patients
with high clinical risk (determined by the online tool) and low
genomic risk (determined by MammaPrint) (176). After
randomization to receive adjuvant chemotherapy or not
following surgery, the difference in survival was small: 1.5%
lower among patients not receiving chemotherapy. Indeed, the 5-
year survival rate without distant metastasis was 95.9% (95% CI:
94.0–97.2) among those receiving chemotherapy compared to
94.4% (95% CI: 92.3–95.9) among patients who were not treatedFrontiers in Immunology | www.frontiersin.org 9with chemotherapy. Thus, MammaPrint is a useful tool for
informing treatment decisions.
Prosigna
Prosigna (also called PAM50 gene signature) is a 50-gene
microarray-based technique developed by Nanostring
technologies (Seattle, USA) for use with fresh and frozen tissue
or formalin fixed paraffin embedded samples. The test classifies
tumors in one of four subtypes: Luminal A, Luminal B, HER2-
positive or Basal-like (88). The test provides a Risk of Recurrence
score (ROR), where low scores (ROR<40) categorize patients as
being low risk, and high scores (ROR>60) categorize patients as
being high risk. Several studies have validated the prognostic value
of Prosigna in postmenopausal women with ER-positive early
breast cancer. For example, a study of 1478 women from the
ABSCSG-8 trial who were being treated with tamoxifen or
tamoxifen and anastrozole, showed that the ROR score from
Prosigna has significant prognostic value (177). This study
showed that the Luminal A subtype presented a lower ROR
score after 10 years compared with Luminal B, emphasizing the
utility of this multiparameter test for predicting the risk of distant
recurrence. Other studies have analyzed the utility of Prosigna for
therapeutic prediction. For example, a randomized controlled
study—the DBCG89D trial—among patients with early breast
cancer treated with either CMF (cyclophosphamide, methotrexate
and fluorouracil) or CEF (cyclophosphamide, epirubicin and
fluorouracil) undertook Prosigna assays on samples from 686
patients and studied associations with distant recurrence, time to
recurrence and overall survival (89). The results showed that
patients from the HER2 subtype presented a significant benefit
from anthracycline-based (epirubicin) chemotherapy, in
comparison with patients from the luminal subtypes, as the time
to distant recurrence was significantly longer in the HER2 subtype
treated with CEF. Further, the benefit of CEF therapy over CMF
was associated with higher ROR scores.
Endopredict
Endopredict is an 8-gene RT polymerase chain reaction
developed by Sividon Diagnostics (Koln, Germany, now part of
Myriad Genetics). The test is usually used with formalin fixed
paraffin embedded samples, and, combined with tumor size and
nodal status, it can predict the clinical risk of distant recurrence
ten years after diagnosis by assigning a score (either low or high).
Endopredict is normally used as a prognostic test for patients
with early breast cancer, who are ER-positive and HER2-negative
(90, 178) however other studies have demonstrated its utility to
inform treatment decisions. A retrospective comparative analysis
of five large clinical trials (GEICAM/9906, GEI-CAM 2003/02,
ABCSG-6, ABCSG-8 and TransATAC trials) analyzed a total of
3746 women, who were treated with either adjuvant endocrine
therapy alone or endocrine therapy plus chemotherapy, and
determined the ability of Endopredict to estimate the 10-year
distant recurrence free interval rates (91). The results showed
that women who received chemotherapy in addition to
endocrine therapy and those who had higher Endopredict
scores, showed significantly lower distant recurrence after 10
years compared to those who only received endocrine therapy.February 2021 | Volume 11 | Article 616188
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The Rotterdam signature is a multi-parameter microarray-based
technique that analyses tumor expression, in fresh or frozen
tissue, of 76 genes involved in cell death, cell cycle, proliferation,
immune response, survival, cell to cell signaling, DNA
replication and repair. These genes do not overlap with
Oncotype DX or Mamma-Print. The Rotterdam signature—so
called due to its development at the Erasmus Medical Centre in
Rotterdam—was designed for lymph node negative breast cancer
patients, to predict metastatic disease over a period of five years.
The model was validated in 171 breast cancer patients and
showed a significant difference of 40% between good and poor
prognosis groups for distant-metastasis-free survival at 60
months and a difference of 27% between groups for overall
survival. This test could predict distant tumor recurrence
regardless of age, menopausal status and tumor size, and could
identify patients with a better prognosis who could avoid
adjuvant systemic therapy (92). Later studies validated the
Rotterdam signature in a large cohort of node negative breast
cancer patients, including those from the TRANSBIG trial
(network of TRANSlational research by the Breast
International Group) (93, 179). Further research is needed for
this index to be used regularly in routine practice.
Summary of Genetic Profiling Tests
Despite the value of the genetic profiling platforms described
above (i.e. Oncotype DX, MammaPrint, Prosigna, Endopredict
and Rotterdam Signature) to inform treatment decisions, these
tests fail to predict recurrence in a fraction of patients,
particularly in those with luminal subtypes (180). Thus, new or
improved tools are needed to accurately predict recurrence and
avoid undertreatment and overtreatment.MEASUREMENTS IN BLOOD
Carcinoembrionic Antigen (CEA)
Carcinoembrionic antigen (CEA) is a cell surface glycoprotein
which is a 641 amino acid polypeptide chain that can be released
into blood by tumor cells. It is the most widely used tumor
biomarker in clinical settings and for several cancers, particularly
carcinomas of the bowel (2). This biomarker, normally assessed
by Enzyme-linked Immunosorbent Assay (ELISA) in plasma or
serum, has also received a lot of attention in breast cancer, as
studies examining its prognostic value have shown that high
levels are associated with poorer outcomes (94, 96, 181). For
example, in a prospective study that measured pre-operative
CEA levels in serum among 2062 breast cancer patients, it was
shown that high levels of CEA (>5 µg/L) in 12.7% of the patients
correlated with nodal involvement and larger tumors (96). In
addition, an elevated CEA level was present in 56.3% of patients
exhibiting cancer recurrence. Furthermore, CEA was found to be
an independent prognostic factor for both disease free and
overall survival regardless of node status. In addition, high
CEA was associated with a high probability of metastasis, as all
patients with >7.5 µg/L had recurrences during the follow upFrontiers in Immunology | www.frontiersin.org 10time. Other studies have examined the predictive value of CEA
and high levels have been associated with poorer responses
to therapy in patients with advanced disease. For example,
in a study of 232 breast cancer patients with recurrent tumors
following mastectomy, an increase of >2 ng/ml after the second
cycle of the therapy correlated with shorter progression-free
survival compared with those with lower/stable levels: 6.7 vs.
17.7 months, respectively (P < 0.001) (95). Furthermore, high
CEA was associated with bone metastases. Despite these
promising results, further studies are required before CEA is
used widely in clinical practice.
CA 15.3 and CA 27.29
CA 15.3 and CA27.29 are mucin-like glycoproteins that belong
to the MUC1 family. Mucins (MUCs) are heavily glycosylated,
high molecular weight glycoproteins with an aberrant expression
profile in various malignancies. The names 15-3 and 27.29 refer
to the specific monoclonal antibodies used for detection. CA 15.3
is most commonly used although CA 27.29 has been shown to
have comparable utility (182). These biomarkers are normally
measured by ELISAs, but also other commercially available kits,
based on radio-, enzyme- or chemi-luminescence. Studies
examining CA 15.3 have shown that high levels of this protein
are associated with worse outcomes and shorter survival (97, 100,
183). For example, one study in 2004 recruiting 600 newly
diagnosed breast cancer patients showed that increased levels
of CA 15.3 prior to surgery (>30 units/L) were associated with
shorter overall survival [hazard ratio (HR) = 2.16, CI, 1.55–3.03,
P < 0.0001], regardless of the type of adjuvant treatment
administered (183). Another study prospectively measured pre-
operative serum levels of CA 15.3 in 2062 breast cancer patients
(96). It was shown that high levels of CA 15.3 (>30 kU/L) in
19.6% of the patients correlated with nodal involvement and
larger tumors. In addition, CA 15.3 was a significant prognostic
factor for disease free survival in the absence of CEA.
Furthermore, rising CA 15.3 assessed with serial blood samples
also predicts poor outcomes. Studies have also confirmed the
predictive value of these biomarkers with several types of cancer
treatment, including chemotherapy. A retrospective study
examined CA 15.3 for predicting response to treatment in 73
patients with locally advanced breast cancer and found that
elevated levels prior to administering of primary chemotherapy
were significantly associated with poor clinical and pathological
response (33). Furthermore, if the elevated levels of CA 15.3 were
sustained following treatment, this appeared to be an
independent predictor of recurrence (P = 0.007). Another
study with 232 breast cancer patients who had recurrent
tumors following mastectomy, analyzed the associations
between CEA and CA 15.3 and the response to therapy (95).
This study found that increased levels of CA 15.3 (an increase of
>15 U/ml) after the second cycle of therapy correlated with
shorter progression-free survival compared with normal levels:
7.7 vs. 17.3 months, respectively for CA 15.3 (P < 0.0001).
Furthermore, elevated levels also correlated with metastases in
the bones. Current evidence does not justify the use of CA 15.3
and CA27.29 for monitoring responses to therapy.February 2021 | Volume 11 | Article 616188
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(MCA)
Mucin-like carcinoma associated antigen (MCA) is another
measurement of MUC-1. Some studies have measured MCA
with other circulating markers, such as CA 15.3, CEA and Tissue
Polypeptide (TPA) (98). Testing two different cut off values for
MCA (11 U/ml and 15 U/ml), it has been shown that MCA is
more sensitive than CA 15.3, CEA or TPA (68 vs. 32%, 10%, 26%
for cut off 11 U/ml and 53 vs. 32%, 16%, 42% for cut off 15 U/ml)
but, less specific than CEA and CA15.3 (42% for cut off 11U/ml
or 73% for cut off 15 U/ml vs. 96% and 97% respectively).
Changes to MCA levels have been related to tumor response to
therapy in metastatic patients and elevated pre-surgical levels
seem to be associated with lower disease-free survival. For
example, a study recruiting 548 participants consisting of 148
primary breast cancer patients, 150 with metastatic breast cancer,
50 patients with benign disease, and 200 participants with no
clinically evident disease, showed an association between higher
pre-surgical levels of MCA with lower disease-free survival,
which appeared to be most significant in those with no nodal
invasion. Also, in the metastatic breast cancer subgroup,
decreases in MCA levels positively correlated with therapeutic
response in 82% of the patients (99). However, few studies have
evaluated the prognostic and predictive value of MCA
individually, precluding its use clinically.
Circulating HER2
The extracellular domain of human epidermal growth factor
receptor 2, also known as extracellular circular domain or ECD,
can undergo proteolytic cleavage and can be released into blood,
and is commonly measured by ELISA. High levels of circulating
HER2 levels have been associated with worse outcomes and
poorer survival, therefore measurement of this protein is a useful
prognostic marker (100, 101). For example, it has been shown
that higher levels of circulating HER2 were associated with a 50%
reduction in overall survival in metastatic breast cancer patients
compared to lower levels (10.1 months, 95% CI: 5.2–13.6 vs. 20.2
months 95% CI: 15.0–28.6, P < 0.001) (100). Some studies have
also shown utility of this marker to monitor cancer recurrence
(184), and the predictive value has been shown by studies
showing that patients with high circulating ECD levels, which
were sustained through treatment, benefited less from
trastuzumab. For example, in a study of 175 breast cancer
patients from the GeparQuattro trial, a >20% decrease in
circulating HER2 throughout the course of treatment was
associated with a 60% chance of pathologic complete response
compared to patients where this decrease was not achieved
through therapy (185). Almost identical results have also been
shown with the response to lapatinib treatment (102).
Circulating PSA
After being secreted by breast cancer cells, PSA likely
accumulates in the tumor microenvironment and eventually
reaches peripheral blood. PSA has been measured in serum
from breast cancer patients, primarily using immunoassays,
and some studies have shown prognostic utility of thisFrontiers in Immunology | www.frontiersin.org 11biomarker in breast cancer management (103, 105, 186).
However, other studies have not been able to demonstrate
prognostic value, despite promising results when PSA is
measured in tissue samples from the tumor (187, 188). In
general, using circulating PSA as a biomarker for breast cancer
among women remains a challenge, as PSA levels are very low
compared to men, and often undetectable (106). Although more
sensitive assays are being developed (104), further research with
large cohorts of patients is required before this marker is used
routinely in breast cancer management.
Circulating Cell-Free DNA (ctDNA)
Apoptotic and necrotic cells can secrete fragments of DNA into
blood, referred to as cell free DNA or cfDNA. If it can be
confirmed that this DNA has come from cancer cells, then this
measurement is better known as circulating tumor DNA
(ctDNA). ctDNA is present at a very low concentration in
plasma and enables non-invasive serial assessments of tumor
characteristics including, assessing point mutations and DNA
methylation in key genes (107). ctDNA is assessed via next
generation sequencing or PCR-based assays. Recently, a ctDNA
assay measuring 110 alpha catalytic subunit of phosphoinositide
3-kinase (PIK3CA) mutations in HER2-negative breast cancer
patients has recently obtained FDA approval (110). Indeed,
studies have confirmed the utility of ctDNA to monitor
metastatic disease. For example, a prospective study examined
plasma from 30 breast cancer patients to compare ctDNA levels,
circulating tumor cells and CA 15.3 levels (108). Using digital
PCR and targeted deep sequencing, somatic mutations or
structural variants in PIK3CA and TP53 genes were screened
for, identified and quantified at different timepoints. It was
shown that the concentration of PIK3CA and TP53 mutations
in plasma significantly positively correlated with increases in
tumor burden, with high levels reflecting progressive disease in
89% of the cases and being associated with shorter overall
survival (P < 0.001). Furthermore, it was suggested that ctDNA
analysis could be predictive of therapeutic response earlier than
CA 15.3 and circulating tumor cells. Other studies have shown
that measurement of ctDNA can identify mutations linked to
resistance to certain treatments, such as anti-HER2 therapy, and
therefore predict treatment failure (109). However, further
research is needed via more high-quality prospective studies,
and standardized methodology, before it is used routinely in
all clinics.
Circulating Tumor Cells (CTCs)
Circulating tumor cells (CTCs) can be found at very low
frequency in blood and just a few CTCs per 10 ml of blood
can predict an aggressive primary tumor or metastasis (20).
CTCs are a heterogeneous group of cell types, such as epithelial
tumor cells, epithelial-to-mesenchymal cells and cancer stem
cells (29). Given their low frequency, enrichment procedures and
highly sensitive assays are required to measure them, and CTCs
can be quantified via microscopy, flow cytometry or using RT-
PCR (113). One of the widely used techniques is the CellSearch
Assay, which has had FDA approval for prognostic and
predictive use in metastatic breast cancer (114). CellSearchFebruary 2021 | Volume 11 | Article 616188
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phenotype as EpCAM+ (Epithelial cell adhesion molecule),
Cytokeratins (8+, 18+, and/or 19+), DAPI+ and CD45−, and
only counts intact cells (intact cell >4 microns). Other methods
are used in research settings, including flow cytometry, RT-PCR,
gene expression arrays, and Fluorescence In Situ Hybridization.
A study recruiting 99 metastatic breast cancer patients,
enumerated CTCs using CellSearch after the second cycle of
chemotherapy and showed that patients with ≥5 CTCs per 7.5 ml
of blood exhibited reduced overall survival (8.7 months vs. 38.5
months, P < 0.001) and reduced progression-free survival (3
months vs. 9.4 months, P = 0.001) compared with patients who
had < 5 cells per 7.5 ml of blood (34). In addition, the clinical
benefit rate was also considerably lower (44 vs. 77%, P = 0.0051).
Similar results were obtained in another prospective study, with
metastatic patients before they started a new line of treatment
(111). Finally, some studies have shown that CTCs can predict
early relapse after neoadjuvant chemotherapy and shorter overall
survival (189) and can predict treatment outcomes (112). Further
validation studies and standardization is required for integration
in clinics.
Immune Profiles
The phenotype and function of immune cells, as well as the T cell
repertoire and diversity in blood, have been examined for
predictive and prognostic utility in the context of breast
cancer. While an individual’s immune profile prior to a cancer
diagnosis might influence clinical outcomes, cancer itself and/or
treatment of the disease might exacerbate immunosenescence,
changing immune profiles, leading to poor outcomes (190). In a
study of 88 breast cancer patients with metastasis treated with
cyclophosphamide or paclitaxel based chemotherapy regimens,
extensive immunophenotyping was conducted in peripheral
blood using flow cytometry (115). It was shown that among
patients treated with paclitaxel, higher frequencies of naïve
CD4+ or CD8+ T cells (CD45RA+CD95−CD27+CD28+) were
associated with worse prognosis, as they correlated with shorter
breast cancer specific survival (CD8+: 28.7 vs. 12.6 months,
HR = 0.32 95% CI: 0.15–0.67, P = 0.0028; CD4+: 29.4 vs. 15.1
months, HR = 0.45 95% CI: 0.22–0.91, P = 0.027). In these
patients, however, higher frequencies of CD11c+ dendritic cells
were linked to better outcomes (13.4 vs. 25.3 months, HR = 4.60
95% CI: 1.23–17.1, P = 0.023). In the cyclophosphamide-treated
group, CD14+ monocytes were also associated with good
prognosis. Another study of 89 women with metastatic breast
cancer showed that a CD8+CD28− cells were significantly
increased compared to age-matched healthy women, and the
frequency of these cells negatively correlated with progression
free survival. The median survival was on average 2 months less
(P < 0.001) among patients with high frequencies of CD8+
CD28− cells (≥24.0% of the CD8+ T cell pool) compared to
patients with a lower frequency (<24.0%) (191).
Some studies have examined whether the capacity of T cells to
recognize tumor-associated antigens is a predictive or prognostic
factor in breast cancer, and in turn, whether other aspects of
immunosenescence influence this response. For example, the
frequency of regulatory T cells and Myeloid derived suppressorFrontiers in Immunology | www.frontiersin.org 12cells (MDSCs: Lin−CD14+HLA-DR−) and HER2-specific T cells
were examined among 40 patients with breast cancer prior to
treatment (192). Patients exhibiting HER2-reactive T cells with
a lower frequency of MDSCs had a 100% rate of survival after
5 years, compared to 38% of patients without HER2-reactive
T cells with higher frequencies of MDSCs (P = 0.03).
Furthermore, patients without HER2-reactive T cells and with
higher levels of regulatory T cells had a 50% chance of survival
compared to 100% survival of patients who mounted an anti-
HER2 response with lower frequencies of regulatory T cells (P =
0.03). This survival advantage appeared to be independent of
metastases (192). Moreover, T cell receptor diversity and
clonality was studied in a group of 26 breast cancer patients. It
was shown that HER2-positive patients displayed greater highly
expanded clone ratios among the CD8+ T cell repertoire and that
greater heterogeneity during chemotherapy was associated with a
better clinical response (116).
Finally, there is concern that the overall immune profile
of individuals , especial ly those exhibit ing signs of
immunosenescence, could influence the effectiveness of some
immunotherapies (193) such as the monoclonal antibodies
atezolizumab and avelumab for treating breast cancer by
targeting PD-L1 (Programmed death ligand 1). This ligand can
be expressed by tumors and other local cells (e.g., fibroblasts,
endothelial cells, antigen presenting cells, myeloid derived
suppressor cells) and inhibit tumor infiltrating T cells and NK
cells which express PD1. Perhaps counter-intuitively, although
PD-L1 is generally expressed at low levels (around 10%) on
tumor cells, it has been shown that expression level positively
correlates with a higher pathological complete response rate to
neoadjuvant chemotherapy (117). However, PD-L1 expression
appears not to be a good predictor of the response to PD-L1
targeting therapies (118). Taken together, these findings
emphasize the importance of a strong anti-tumor immune
response, hence the development of anti-PD1 therapies which
target T cells and NK cells directly, such as pembrolizumab
(118). Indeed, the capacity to mount a strong anti-tumor
response is likely to be influenced by the characteristics of the
patient such as immunosenescence but also the characteristics
of the tumor given that tumor mutational burden is a strong
predictor of the effectiveness of anti-PD1/PD-L1 treatment
(118, 119).THE RELEVANCE OF AGING AND
LIFESTYLE FOR CANCER BIOMARKER
PROFILING AND DISEASE PROGRESSION
Aging Influences Tissues and Blood
Aging is a temporal and progressive decline in the integrity of
different physiological systems in an organism, consisting of
tissue-specific changes characterised by processes such as
inflammation and cellular senescence (41). These changes
affect the functional properties of most cells, tissues and
organs. One feature of aging is a gradual accumulation and
redistribution of adipose tissue and a change to its cellularFebruary 2021 | Volume 11 | Article 616188
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prominent within the abdominal cavity, but ectopic deposition
also occurs around organs and within skeletal muscle (195, 196).
Aging contributes to dysfunction of adipose tissue, characterised
by changes to the tissue microenvironment at structural and
cellular levels, resulting in abnormal secretions derived
predominantly, from adipocytes and resident immune cells
(197). Changes to the tissue include adipocyte hypertrophy,
hypoperfusion, hypoxia, impaired insulin signaling, and
accumulation of macrophages with a pro-inflammatory
phenotype and infiltration of other inflammatory immune
cells, such as sub-populations of T cells. In turn, adipose tissue
dysfunction contributes toward a change in physiology at a local
level (e.g., effects on the surrounding tissues, which could
include, tumors for example) but also at a systemic level (e.g.,
low-grade inflammation and insulin insensitivity). Aging is also
associated with a decline in muscle mass, muscle strength and
changes to the myokinome (198–200). This muscle secretome
consists of many cytokines and other soluble mediators
produced by skeletal muscle in response to contractions during
exercise. These so-called “exercise factors” are released into the
circulation and exert endocrine or paracrine functions in other
cells, tissues or organs, which has relevance for disease risk and
progression (201). Interleukin-6 (IL-6) is the most well-
characterized myokine and its roles when secreted from muscle
are considered to be positive rather than pro-inflammatory, and
include promoting glucose uptake, insulin sensitivity, lipolysis
and fatty acid oxidation. However, in other contexts IL-6 is
considered a mediator of inflammation, and so this cytokine is
sometimes referred to as being pleiotropic; whereby depending
on the context and the site of production, it can be pro- or anti-
inflammatory (202, 203).
Inflammation is a self-limiting process which consists of
a complex network of chemical signals triggered in the
presence of damage for healing purposes, upon infiltration
of pathogens as part of an immune response, or due to
adipose tissue dysfunction (204). Inflammation can directly
affect pathogens, such as by C-Reactive Protein activating
complement (205), interferons limiting viral replication or by
stimulating other immune processes, including attracting
immune cells (206). The term inflammaging refers to the
sustained low-grade inflammation that is characteristic of
aging, and consists of higher levels of cytokines, such as IL-6
and TNF-alpha, increased levels of glucocorticoids and decreased
levels of insulin-like growth factor 1 (207). Inflammaging has
also been associated with deregulation of the complement
pathway and increased activation of coagulation processes
(208). Inflammaging leads to, or is part of, the age-associated
decline and functional deterioration of immune competency,
referred to as immunosenescence (209). The most accepted
hallmarks of immunosenescence are lower numbers of naïve T
cells and higher numbers of memory T cells, particularly within
the CD8+ T cell pool (210). Sustained antigenic stimulation due
to viral infection, especially Cytomegalovirus (CMV), drives these
changes among T cells, but some cells accumulate with age per se
(211), or as a result of other infections or perhaps evenFrontiers in Immunology | www.frontiersin.org 13sub-clinical malignant transformation (212–214). Further,
aging leads to impaired function of neutrophils, dendritic cells
and natural killer cells, and increased frequencies of regulatory T
cells and myeloid-derived suppressor cells (215). Most of these
changes are very evident and well established in blood, but
research characterizing inflammatory and immunological
processes in tissues is limited.
Although it is likely that key mechanistic links between aging,
cancer risk and tumor progression feature within inflammatory
and immunological processes, it is important to emphasise that
aging affects the structure and function of almost all aspects of
physiology (41). In principle, a positive development in cancer
care would be to incorporate measurements of aging into routine
clinical tests and decision making to provide an estimate of
a patient’s biological age. Despite the quest for a single and
easily measured biomarker of aging, a range of blood and
tissue biomarkers would need to be assessed. Aside from
inflammatory and immunological parameters, assessing age-
associated changes to a variety of body systems might be
recommended, including the cardiovascular system (e.g., blood
pressure, homocysteine), metabolic health (e.g., cholesterol,
glucose, leptin), the central nervous system (e.g., amyloid b42,
Tau), the hypothalamic pituitary axis and sympathetic nervous
system (e.g., cortisol, DHEA, IGF-1, adrenaline, noradrenaline)
(216). In addition, a number of genetic markers have been
proposed, such as particular alleles of apolipoprotein E,
polymorphisms in the gene encoding angiotensin-converting
enzyme, mutations in mitochondrial DNA, telomere length,
and many epigenetic changes (216–218). Recent emphasis has
been placed on measuring the accumulation of senescent cells
with aging. For example, by assessing DNA damage pathways
and cyclin-dependent kinase inhibitors (e.g., p16INK4a),
characterizing a senescence-associated secretory phenotype and
apoptosis resistance, or determining morphological changes,
such as lysosome accumulation (e.g via beta-galactosidase
activity) or plasma membrane disturbances (e.g., caveolin-1
upregulation) (219). Finally, it might be recommended that a
panel of aging biomarker measurements are interpreted
alongside integrated whole-body measurements of physical
functioning and frailty (e.g., sit-to-stand tests, walking tests,
muscle function tests) (220).
Aging Influences Tumor Progression
and Cancer Outcomes
Given the constellation of changes that happen over the life
course as time elapses, both chronological and biological aging
are associated with increased cancer risk. Older people are more
likely to get cancer, the majority of cases occur in people over 65
years of age (221). Given that life expectancy has significantly
increased in the last century (222), around 30% to 40% of
patients with breast cancer are over 70 years of age (223), and
yet this population is underrepresented in clinical trials (224).
Older age is associated with faster disease progression, and more
complications, including treatment resistance (225). Indeed,
menopausal status has a very strong influence on breast cancer
risk, tumor characteristics, and disease progression (226).February 2021 | Volume 11 | Article 616188
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influenced by late/delayed diagnosis and undertreatment, a
variety of other age-associated mechanisms likely contribute, of
which some, interact with inflammation.
Deregulation of normal inflammatory processes is
characteristic of aging, including a sustained release of pro-
inflammatory cytokines, which can damage cells, and lead to
an accumulation of damaged cells in tissues, which could
conceivably progress into a malignancy (215, 227). Moreover,
reactive oxygen species released by neutrophils in inflammatory
settings can also damage cells, by oxidizing proteins, lipids and
DNA (228). Once a tumor has developed, the levels of some
cytokines have been associated with worse outcomes among
patients. This is the case of IL-6, for example, as high serum
levels appear to be linked with higher rates of metastasis and
shorter survival in breast cancer patients (229, 230). Indeed,
mechanistic studies have implicated IL-6 treatment resistance.
For example, an in vitro study of drug-sensitive and drug-
insensitive breast cancer cell lines showed that IL-6 was
present at a high concentration in the media of drug-
insensitive cells, but absent in the media of drug-sensitive cells
(231). In addition, pre-treatment of drug-sensitive cells with IL-6
for 10 days caused an 8–10 fold increase in the resistance to the
chemotherapeutic agent doxorubicin, and when drug-sensitive
cells were transfected to constitutively express the IL-6 gene,
drug resistance was shown to be 70-fold higher as compared with
the drug-sensitive cells. Thus, it is conceivable that inflammaging
could be one explanation for the treatment resistance that is
sometimes seen among older people.
While several cytokines have well-established pro-tumor
effects (e.g., IL-1, IL-4, IL-6) and can be produced by tumors
directly in an autocrine manner (232), not all cytokines
contribute toward pro-tumor processes. Indeed, many
cytokines may elicit anti-tumor effects, including IL-2, IL-12,
IL-15, IL-21, IFN-alfa and Granulocyte-Macrophage Colony-
Stimulating Factor GM-CSF (233). Some of these cytokines
have anti-inflammatory roles and can interfere with cancer
progression, either by enhancing anti-tumor immunity—
stimulating certain immune cells—or by exerting direct anti-
proliferative or pro-apoptotic actions on tumor cells directly
(234). These properties have been explored in cytokine-based
immunotherapy trials, either as monotherapy or in combination
with other therapeutic agents (235). IL-2, for example, promotes
survival, expansion and differentiation of activated NK and T
cells, and its use in immunotherapy is approved for the treatment
of metastatic disease in renal cell carcinoma and melanoma
(236). IFN-alfa has been shown to exert anti-proliferative, pro-
apoptotic and anti-tumor activity on cancer cells, and is
approved to treat Hairy cell leukemia, AIDS-related Kaposi’s
Sarcoma, Chronic Myelogenous Leukemia, Malignant
Melanoma and Follicular lymphoma (237). However,
challenges remain with these therapies, including short half-life
of the cytokines, low response rates and frequent adverse events
with high doses (238). However, it is conceivable that in older
adults who might exhibit lower basal levels of IL-2 or IFN-alfa, or
might have an impaired capacity to produce these cytokinesFrontiers in Immunology | www.frontiersin.org 14(239, 240), these individuals might exhibit a greater risk of cancer
and poorer anti-tumor responses. Indeed, the shift to a pro-
inflammatory phenotype is well-known with aging (241) and
some evidence shows this profile is reversed in extremely old
populations, termed ‘anti-inflammaging’ (242, 243).
More broadly, other aspects of an aging immune system
have been linked with unexpected hospitalisations during
chemotherapy and limited effectiveness of some treatments—in
particular immunotherapies—among older people (244–246). It
is thought these effects might be partly attributed to the
reduction of the naïve T cell pool, as this translates into an
impaired ability to recognise and eliminate malignant cells. In
addition, the senescence associated secretory phenotype (SASP)
that some cells in aging tissues adopt, characterized by aberrant
production of a range of cytokines, growth factors, proteases, and
chemokines, could also play a role in tumorigenesis and
progression (247). Finally, studies have shown that other
markers of immunosenescence, including high frequencies of
CD8+CD28− T cells, regulatory T cells, and myeloid-derived
suppressor cells are associated with shorter survival (191).
Aging Influences Cancer
Biomarker Profiles
Evidence shows that the levels and characteristics of some cancer
biomarkers, that are routinely measured in tissues and in blood,
can be influenced by aging, which could affect the interpretation
of clinical measurements and treatment outcomes. For instance,
cross-sectional studies have shown that simple biomarkers
measured in plasma, which are implicated in cancer risk and
disease progression, can be influenced by aging (and also other
factors that change with aging, including physical activity and
body composition). For example, 77 cancer and inflammatory
biomarkers were assessed in plasma from 1005 individuals from
the Northern Sweden Population Health Study, and the influence
of 158 inter-individual factors, was assessed (248). The results
showed that 18 factors including age had a significant influence
on the levels of one or more of 52 of the 77 biomarkers (248). In
another study, plasma IGF-1 and serum IGFBP-3 were assessed
in samples from 364 women with intraepithelial neoplasia or
early invasive breast cancer and compared to 376 unaffected
women (249). Women with early breast cancer had 21% higher
IGF-1 and 19% higher IGFBP-3 than unaffected women,
however IGF-1 levels were negatively associated with age (and
also BMI) across all groups (249). Similar relationships have been
shown with other biomarkers, for example, preoperative serum
levels of CEA were shown to significantly positively correlate
with age at diagnosis and menopausal status (250).
Some of the strongest evidence of aging influencing cancer
biomarkers comes from studies that have considered the
menopause. For example, differences in tumor characteristics
were examined among 428 pre- and post-menopausal women
(251). Compared with post-menopausal women, pre-
menopausal women had significantly larger tumors (21% of
pre-menopausal women had tumors of >5cm of diameter vs.
12% of post-menopausal women, P = 0.047). In addition, pre-
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lymph nodes vs. 56% of post-menopausal women, P < 0.001) and
more likely to have a positive expression of estrogen and
progesterone receptors (ER: 56% of pre-menopausal women
had positive expression vs. 44% of post-menopausal women,
P = 0.002. PR: 52 vs. 41%, respectively, P = 0.014). Finally, pre-
menopausal women had tumors with a greater proliferative
capacity as shown by the higher likelihood of KI-67 positivity
(33% of pre-menopausal women were KI-67 positive vs. 22.8%,
of post-menopausal women, P = 0.017). Post-menopausal
women, on the contrary, had significantly higher likelihood of
expression of HER2 (pre-menopausal women: 2% vs. post-
menopausal women: 19%, P = 0.038). Menopausal status also
influences treatment decisions, and post-menopausal women
were significantly more likely to have breast conserving surgery
(P = 0.004), chemotherapy (P = 0.007), radiotherapy (P = 0.008),
and endocrine therapy (P = 0.025) than pre-menopausal women.
These results highlight important differences in breast tumors
depending on menopausal status, which translate into differences
in treatment and outcomes. However, other studies have
suggested that age itself may be a stronger determinant of
biological and etiological heterogeneity in breast tumors than
menopausal status (252).
Aging in general is associated with particular molecular
subtypes of breast cancer and a differential expression of some
tumor biomarkers. For example, a study evaluated several
makers by immunohistochemistry in different subtypes of
invasive breast cancer among two groups (162 women ≤40
years and 100 women ≥50 years) (253). The results showed
that Triple Negative Breast Cancer and HER2 subtypes were
more common among young women. Furthermore, young
women were more likely to have ER-negative tumors overall
(253). In this work, tumor size and characteristics (ER, PR,
HER2, Ki-67 and p53) were also compared (253). tumors from
younger women were found to be significantly larger than those
from older women; approximately 1.03 cm larger on average (P =
0.01). In addition, there was a significant quantitative differential
expression of the tumor biomarkers on the basis of age. Younger
women presented with lower expression levels of ER and PR
(25% lower for ER, P < 0.01 and 10% lower for PR, P = 0.03), and
higher levels of Ki-67 and P53 overexpression (10% higher for
Ki-67, P = 0.01 and 13% higher for P53, P < 0.01) compared with
women in the older group. Another study evaluated the influence
of both age and menopausal status on several prognostic
biomarkers in 1226 patients with operable primary breast
cancer (254). Patients were divided into four groups: ≤40
years, premenopausal >40 years, postmenopausal <75 years
and ≥75 years. The results showed that youngest patients had a
worse prognosis, which improved with increasing age. Younger
patients had the highest infiltration of TILs (P < 0.001), greatest
p53 and Ki-67 expression (both P = 0.01) and the lowest
expression levels of ER (P < 0.001). Finally, ER was also
influenced by menopausal status, as expression level was
higher in postmenopausal women compared to pre-
menopausal counterparts (P < 0.001). Similar results have been
found in larger studies (255). For example, by assaying 3800Frontiers in Immunology | www.frontiersin.org 15tumor samples, significant inverse correlations with age and
biomarkers of tumor growth and genetic instability (e.g., Ki-67
and p53 positivity) and growth factor receptor over expression
(e.g., ErbB2+ or EGFR+) were shown (all P = 0.05), and among
ER+ tumors, ER expression was significantly positively
correlated with age (P < 0.0001). Likewise, a potential age-
related association between HER2 and PR was evaluated in a
study that examined 1104 ER positive tumors (divided into two
age groups, 173 women of ≤45 years and 931 women
of >45 years). There was an inverse relationship between HER2
and PR only in the group of women >45 years old (P =
0.001) (256).
There is an increasing interest on how factors such as age can
affect TILs. A study examined TILs in young (35–45 years),
middle-aged (55–65 years) and older (>70 years) patients with
luminal B (ER+PR+HER2−) breast cancer (257). TILs were
phenotyped using CD3, CD4, CD5, CD8, CD20, CD68 and
FOXP3 with immunohistochemistry. The results showed that
increasing age was associated with a decrease in the overall
percentage of stromal TILs in biopsies (P = 0.025). In addition,
age had a significant effect on the composition the tumor/
immune infiltrate, including a lower density of certain immune
cells identified using CD3, CD5, CD8 and CD20, which was
significant in all tumor regions (P < 0.042). The proportions of
CD8+ TILs also decreased significantly with age in all tumor
regions (P < 0.0001). However, the distribution patterns of
TILs across each tumor region did not differ with age.
Likewise, another study quantified the abundance of the
immune cell infiltrate (B cells, CD4+ and CD8+ T cells,
neutrophils, dendritic cells and macrophages) in tumors using
transcriptome datasets. It was shown that there were no
significant differences in the frequency or composition of TILs
between age groups (young group: <40 years, old group: ≥40
years), but high levels of TILs, and in particular, CD8+ T cells,
were associated with better clinical outcomes (P < 0.04) in
women under 40 years of age (258).
Other studies have examined whether the multi-parameter
molecular profiling tests, including IHC4, Oncotype Recurrence
Score (RS) and Prosigna Risk of Recurrence Score, are influenced
by age (259). Data from 940 women in the transATAC trial was
split across three age groups (group 1: ≤59.8 years, group 2: 59.8–
68.2 years and group 3: >68.2 years). The results showed that the
prognostic performance of all molecular scores significantly
differed with age, with the lowest scores among older patients.
For example, for both IHC4 and Oncotype RS, their prognostic
value appeared to be strongest in the lowest age group or group 1
(IHC4: group 1 HR = 3.01, 95% CI: 1.99–4.53, vs. group 2: HR =
1.67, 95% CI: 1.23–2.26 vs. group 3: HR = 1.64, 95% CI: 1.25–
2.15. Oncotype RS: group 1: HR = 2.16, 95% CI: 1.62–2.87 vs.
group 2: HR = 1.39, 95% CI: 1.16–1.66 vs. group 3: HR = 1.38,
95% CI: 1.11–1.73). However, Prosigna had the most prognostic
value in women between 60 and 68 years or group 2 (group 1:
HR = 3.87, 95% CI: 2.21–6.78 vs. group 2:HR = 4.51, 95% CI:
2.87–7.10 vs. group 3: HR = 1.83, 95% CI: 1.28–2.60). The
influence of age on other more recent biomarkers, including
CTCs and ctDNA has also been examined. For example, oneFebruary 2021 | Volume 11 | Article 616188
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older age and ctDNA positivity among 31 primary breast cancer
patients scheduled for neoadjuvant chemotherapy (260).
An Active Lifestyle Is Associated With
Better Cancer Outcomes
In addition to the robust evidence linking a physically active
lifestyle with a reduction in breast cancer risk (261), studies are
beginning to show that both exercise and physical activity are
beneficial during cancer treatment and in the years after. The
terms “exercise” and “physical activity” are sometimes used
interchangeably, and there is an important distinction that has
implications for the recommendations made in a cancer setting.
For example, the term ‘‘physical activity’’ includes leisure-time,
occupational, home-based and transport-related activities, some
of which, might be undertaken as normal activities of daily living.
The term “exercise” refers to a component of physical activity
(within the leisure-time domain) and comprises physical
activities that are planned, structured, repetitive and
undertaken for the purpose of improving or maintaining
components of physical fitness and/or sporting performance
(262). In many studies, individuals are referred to as being
‘‘active’’ or ‘‘inactive’’ and these terms infer that individuals
undertake (or fail to undertake) a defined level of physical
activity (e.g., such as the recommendations published by the
World Health Organization). Overall, patients with cancer are
advised to lead a lifestyle that is as active as symptoms allow,
whether this is through structured exercise or being physically
active via activities of daily living, and specific guidelines have
been developed for all stages of disease (263–265). For example,
in general, patients are recommended to undertake around
150 min of moderate-intensity physical activity each week,
which if achieved in a structured way, could be in bouts of
around 30 min on 5 days of the week. Alternatively,
recommendations also promote around 75 min of vigorous
physical activity per week and advise supplementing this
aerobic exercise with strength training on at least two days of a
week. These recommendations are largely based upon those
advocated by the World Health Organization and other bodies
for the general population (266). However, very recently, more
specific recommendations have been developed for patients with
cancer, focusing in particular, on structured exercise training
(267). For example, unique recommendations have been made
for patients with complications (e.g., metastases) and for
targeting particular side-effects and symptoms of disease and
treatment (e.g., anxiety, fatigue, lymphedema, physical function)
(267). For example, to counter fatigue, aerobic exercise training
at moderate intensity for at least 12 weeks, exercising for 30 min
three times a week has been recommended. Whereas for other
complications, such as lymphedema, supervised resistance
exercise training in a progressive manner two or three times
per week is recommended.
Aside from the distinction between structured exercise and
physical activity, many studies have shown that leading a
physically active lifestyle generally brings about benefits, but
studies that have employed structured and supervised exerciseFrontiers in Immunology | www.frontiersin.org 16training provide the strongest evidence. Benefits include limiting
treatment toxicity and alleviating cancer-related symptoms such
as fatigue, anxiety, depression, and improving quality of life
(QoL), mood and self-esteem (268, 269). For example, a
randomized and controlled trial investigated the effects of
exercise training on QoL and cardiorespiratory fitness among
53 postmenopausal breast cancer survivors (270). Women were
either assigned to an inactive control group (n = 28) or were
asked to exercise on cycle ergometers three times per week for 15
weeks (n = 25). Exercise was shown to increase overall QoL by
9.1 points compared to 0.3 points from the control group (mean
difference, 8.8 points; 95% CI: 3.6–14.0; P = 0.001). Further,
exercise also increased peak oxygen consumption by 0.24 L/min,
whereas this decreased by 0.05 L/min in the control group (mean
difference, 0.29 L/min; 95% CI: 0.18–0.40; P < 0.001). Moreover,
a meta-analysis investigated effects of exercise interventions on
QoL, social functioning, and physical functioning of breast
cancer survivors in 18 trials (exercise group = 602 participants;
control group = 603 participants) (271). The pooled effect
confirmed that exercise significantly improved QoL (SMD =
0.35; I2 = 61%; 95% CI: 0.15–0.54; P = 0.0004), social functioning
(SMD = 0.20; I2 = 16%; 95% CI: 0.08 to 0.32; P = 0.001), and
physical functioning (SMD = 0.32; I2 = 32%; 95% CI: 0.20–0.44;
P < 0.00001). Remaining active during cancer treatment has also
been shown to improve clinical outcomes (268) and to enhance
the efficacy of various cancer treatments (272). Other studies
have shown that high levels of physical activity are associated
with improved survival and lower levels of cancer recurrence
(35–37). The mechanisms underlying these observations have
not been proven, however likely explanations include exercise
and physical activity influencing the effectiveness of treatment
and modulating the properties of tumors both indirectly
and directly.
An Active Lifestyle Might Lead to Better
Cancer Outcomes Due to Improved
Chemotherapy Completion Rates
Patients who remain active during the period when they receive
chemotherapy are more likely to tolerate a greater dose and
complete their treatment (273, 274). For example, a study
evaluated the potential benefits of aerobic and resistance
exercise among 243 breast cancer patients undergoing adjuvant
chemotherapy (273). Patients were randomly assigned to either
supervised resistance exercise (n = 82), supervised aerobic
exercise (n = 78) or usual care (n = 82), for a median of 17
weeks. Chemotherapy completion rate was assessed as the
average relative dose intensity (RDI) from the originally
planned regimen, and it is known that patients who receive an
RDI of >85% have better outcomes. It was shown that patients in
the resistance exercise training and the aerobic exercise training
groups had better completion rates when compared to the usual
care group, although this was only statistically significant for the
resistance exercise regimen (RDI =84.1% control group vs. RDI=
89.8% resistance exercise group; mean difference=5.7%; 95% CI:
0.4–11.0; P < 0.033). Another study with a comparable group of
breast cancer patients (n = 230) also compared usual care withFebruary 2021 | Volume 11 | Article 616188
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moderate-high intensity supervised regimen combining aerobic
and resistance exercises during a period of chemotherapy
treatment (274). This study evaluated chemotherapy and
trastuzumab completion rates and found that moderate-high
intensity exercise improved completion rates, as a significantly
lower number of patients in this group required chemotherapy
dose adjustments compared to other groups (12%moderate-high
intensity vs. 34% low-intensity vs. 34% usual care, P < 0.002). In
addition, a smaller percentage of patients in the moderate-high
intensity group required a delay or termination of trastuzumab
therapy compared to the other two groups (6% moderate-high
intensity vs. 24% low-intensity vs. 28% usual care). It is worth
highlighting that the home-based exercise was not supervised
and was of lower intensity, whereas the most effective intervention
employed exercise that was supervised and of moderate intensity.
Generally, supervised exercise, and activities that are more
demanding, elicit more robust effects.
Exercise and Physical Activity Influence
Cancer Biomarker Profiles
There is a need for further research examining whether
exercise and physical activity influence cancer biomarker
profiles. Most evidence in support of this concept shows that
broader factors, which are not necessarily cancer-specific, but
are linked to clinical outcomes, including immune competency,
inflammation, and metabolic health, can change among patients
who modify their lifestyle (190). For example, a systematic
review of 45 articles, including a variety of observational
studies and randomized control trials of different designs,
summarized the effects that physical activity in general can
have among cancer survivors on biomarkers (275). This
analysis included the HEAL (Health, Eating, Activity and
Lifestyle) study, an observational prospective cohort study of
746 breast cancer survivors. It was concluded that regular
physical activity can lead to immunological benefits (e.g.,
natural killer cell cytotoxicity, increased T cell proliferation),
positive changes to proteins involved in insulin-signaling
pathways (e.g., C peptide, insulin-like growth factors) and
decreases in systemic inflammation (e.g., C-Reactive Protein,
serum Amyloid A). Similar conclusions were drawn by a pooled
analysis of three randomized controlled trials examining the
influence of resistance exercise on factors that have been linked
to poor cancer prognosis, including C-reactive protein, IL-6, IL1-
beta, insulin-like growth factor binding proteins, leptin, serum
amyloid A, adiponectin and TNF-alpha (276). Post-menopausal
breast cancer survivors were allocated to either 1 year of
resistance exercise consisting of two 1 hour supervised classes
and one 45-minute home-based session each week (n = 109) or
to a control group who undertook stretching and relaxation
exercises (n = 106). It was shown by each trial that resistance
training reduced systemic inflammation and improved
insulin signaling.
A limited number of studies have examined the effects of
exercise and physical activity on cancer-specific biomarkers. For
example, a study of 15 females with breast cancer investigated theFrontiers in Immunology | www.frontiersin.org 17influence of 8 weeks of aerobic exercise training on serum levels
of CEA and CA 15.3 (277). Participants exercised three times a
week, at a light-to-moderate intensity. The results showed that
participants exhibited a significant reduction in their BMI, body
fat percentage, and body mass (P = 0.0001) and there was a trend
for a decline in the levels of CA 15.3 (P = 0.091). There was no
significant change in CEA. Another study, examined whether 12
weeks of structured exercise affected CEA among 54 healthy
elderly women (70–77 years), randomized to different groups,
varying on the frequency of exercise undertaken (278). The
results showed that CEA significantly decreased in all groups
with the largest decrease (percentage change: −59 ± 5%) among
women who exercised 2–3 days per week.
Exercise and Physical Activity Affect
Tumors Directly and Indirectly
Exercise and physical activity lead to changes in tumor
characteristics, including angiogenesis and enhanced tumor
blood perfusion (due to an increase in tumor blood vessel
density, function and maturity, which leads to reductions in
intratumoral hypoxia), impaired growth and increased immune
cell infiltration (279–283). These changes are clinically relevant
as they may enhance the efficacy of some therapies, such as
chemotherapy or immunotherapy, by facilitating the delivery of
drugs to the tumor, and increased tumor vascularization and
blood perfusion could facilitate immune-surveillance and
processes such as reactive oxygen species production by some
immune cells and treatments (272).
For example, a study in 50 athymic female mice evaluated the
effects of 6 weeks voluntary wheel running on breast cancer
growth and progression (279). Half of the mice were allocated to
an active group with access to a running wheel and the other half
were a control group with no access to a running wheel. Mice
were implanted with human breast cancer cells on the first day of
the study. During the intervention, tumor growth was
monitored, as well as several markers of tumor blood
perfusion, hypoxia, vascularization and angiogenesis. After 6
weeks, although no statistically significant differences were
found between the groups for tumor growth or survival, access
to a running wheel changed many tumor charactetistics. The
active group exhibited increased intratumoral vascularization
and blood perfusion, but also an increase of hypoxia-inducible
factor 1 (HIF-1). In this study, mice were athymic and therefore
lacking T cells, which may explain why tumor growth and overall
survival was not affected. Indeed, even more encouraging results
have been shown by another study of a very similar design but
with immunocompetent animals. Mice allocated to a voluntary
exercise condition were compared to a control group (n = 11–12
per group) and it was shown that the exercise group had a
significantly lower tumor growth rate (P < 0.012), higher tumor
apoptosis (P = 0.048), greater microvessel density (P = 0.004) and
increased tumor vessel maturity, as determined by colocalization
of CD31 with desmin (281). However, different to the previous
study, intratumoral hypoxia was significantly reduced in the
active group compared to the control group (P = 0.012). Most
importantly, this study examined interaction between exerciseFebruary 2021 | Volume 11 | Article 616188
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recieve no treatment, exercise only, cyclophospamide only,
or exercise combined with cyclophosphamide (n = 17 per
group). It was shown that the combination of exercise and
cyclophosphamide had the most striking impact on slowing
tumor growth, providing initial evidence that exercise and
the adaptations that may follow, improve the delivery of
chemotherapy to tumors.
Similar to an improvement in the delivery of drugs to sites
where they are needed, physical activity may also enhance the
ability of immune cells to migrate to tumors. For example, one
study examined a number of cancer models in mice, including
breast cancer. Mice were randomized to four weeks of voluntary
wheel running, or to a non-running control group prior to
tumor cell inoculation. Additional groups were designed to
examine questions related to the timing of exercise relative
to tumor formation (284). Overall, physical activity resulted in
a significant accumulation of tumor infiltrating immune cells,
including natural killer cells, CD3+ T cells and dendritic cells,
which appeared to be mediated, at least among natural killer
cells, by IL-6 and epinephrine. Physical activity was also linked
with an upregulation of pathways associated with inflammation
in the tumor (e.g., increased gene expression for IL-1-beta,
IL-6, TNF-alpha) and immune function (e.g., increased
gene expression of NKp46, NKG2D, CD68, CD209, CD8,
CD74, FoxP3). Other studies have shown that reduction of
hypoxia can also facilitate the infiltration of these immune
cells is tumors in mice (285), and given that exercise has been
shown to reduce tumor hypoxia, this might be another exercise-
induced mechanism that facilitates the homing of immune
cells to tumors. However, although some tumor infiltrating
lymphocytes may have a beneficial role (e.g., CD8+ T cells) in
tumor control (286), other cells, such as myeloid derived
suppressor cells could have the opposite effect promoting
tumorigenesis, tissue-destruction and metastases (287).
There are likely to be many other characteristics of tumors
that could be affected by physical activity or exercise, but the
effects on treatment and clinical outcomes may remain
unknown. For example, one study has indicated that exercise
reduces oxidative stress in breast tumors, as shown by 3-fold
lower levels of 8-oxo-dG—a marker of oxidative damage to DNA
—when examining tumors from a group of mice that had access
to a running wheel compared to controls (288). It has also been
hypothesized that physical activity and exercise may counter the
dysregulated energy metabolism of cancer cells, which is
characterized by high glucose uptake and glycolysis (289).
Studies in rats injected intraperitoneally with the carcinogen 1-
methyl-1-nitrosourea showed that rats with free access to
running wheels exhibited less cancer incidence and a lower
average number of tumors per rat compared to controls (290).
The exercising rats also showed changes in blood levels of
hormones and growth factors involved in glucose metabolism,
as reductions in plasma insulin, insulin-like growth factor 1
(IGF-1) and leptin were shown. In support, breast cancer bearing
mice undergoing 7 weeks of endurance exercise training studied
showed that in addition to a reduction in tumor mass, there wasFrontiers in Immunology | www.frontiersin.org 18also a significant decrease in the levels of tumor lactate compared
to untrained controls (291). Exercise training also resulted in
significant changes in the levels of some enzymes that are
essential for sustaining a glycolytic phenotype of tumor cells.
For example, lactate dehydrogenase isoforms A and B, and
monocarboxylate transporter 1 were decreased in tumors from
trained mice, which, in combination with lower lactate
production, could contribute to slower tumor progression.
Indeed, excess of lactate anaerobic metabolism in cancer cells
has been associated with poorer activation, infiltration and
function of immune cells within the tumor (292). Therefore,
these metabolic findings support the positive impact of exercise
in enhancing anti-cancer immunity that may improve
treatment outcomes.
Despite some very advanced studies with animal models,
mechanistic research with human participants examining the
effects of exercise on tumor characteristics and clinical outcomes
is limited. Indeed, most mechanistic insight in human settings is
limited to review articles, which summarize that better clinical
outcomes among more active patients, are likely to be linked to
mechanisms related to metabolic growth factors, inflammation,
immune function, myokines and adipokines (293). Indeed, some
understanding of how exercise and physical activity can affect
tumors directly comes from studies that have incubated cancer
cell lines with human serum collected before and after exercise.
For example, a study collected serum from breast cancer
survivors before and after a 6-month exercise training
intervention (i.e. to examine chronic effects of exercise) and
before and after a 2 hour bout of exercise (i.e. to examine acute
effects) (294). Breast cancer cell lines were grown in human
serum for 48 hours and the effects on viability was examined.
Serum samples collected before and after the exercise training
intervention provided evidence of a reduction in systemic
inflammation shown by lower IL-6 and TNF-alpha post-
intervention, but these serum samples had no anti-growth
effect on the breast cancer cell lines. However, serum samples
collected immediately after an acute bout of exercise—which, as
expected, exhibited a high concentration of adrenaline,
noradrenaline, lactate and IL-6—reduced the viability of the
breast cancer cell lines by approximately 9% (294). Subsequent
work showed that breast cancer cells grown in this acute-
exercise-conditioned serum were 50% less tumorigenic when
implanted into mice, due to adrenaline and noradrenaline
activating the Hippo signaling pathway, and subsequent
phosphorylation of the YAP protein, reducing the expression
of genes associated with proliferation (295).
Prospective cohort studies with patients are ongoing, such as
the AMBER study, which is examining relationships between
physical activity and health related fitness with treatment
outcomes among 1500 newly diagnosed breast cancer patients
(296). Physical activity is measured objectively using wearable
devices, cardiorespiratory fitness is assessed directly, along with
body composition using dual x-ray absorptiometry, and clinical
measurements such as lymphedema and fatigue are also being
recorded. However, most importantly, molecular measurements
in tumors will be interpreted alongside clinical outcomes,February 2021 | Volume 11 | Article 616188
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studies which have investigated the relationship between
exercise and treatment outcomes with cellular and molecular
measurements, is a randomized clinical trial of 20 breast cancer
patients undergoing neoadjuvant chemotherapy (297). One
group underwent a standard period of doxorubicin and
cyclophosphamide treatment, whereas another group received
this chemotherapy with supervised aerobic exercise training.
Exercise reduced systemic inflammation, but increased some
angiogenic factors, including proangiogenic factor placenta
growth factor (PLGF). In addition, circulating endothelial
progenitor cells increased, which might contribute toward
tumor vessel normalization and the reduction of hypoxia,
shown by animal studies. However, this study was unable to
examine whether exercise improved the clinical response to
chemotherapy due to power.
Other human studies provide more indirect evidence of
exercise-induced mechanisms that might benefit patients with
cancer. For example, it is very well established that acute bouts of
exercise cause a transient lymphocytosis and a subsequent
lymphocytopenia in the hours after, whereby lymphocytes with
strong tissue-migrating and effector capabilities, migrate to
peripheral tissues searching for antigens (298). This effect is
particularly marked among T cells and natural killer cells, and is
thought to represent immunosurveillance, that may even
facilitate the detection and elimination of tumors (42, 298–
300). The concept that regular exercise might bolster aspects of
immune function has been shown by a randomized and
controlled trial in breast cancer survivors (301). Participants
were randomized to either aerobic exercise training for 15 weeks
three times per week (n = 25), or an inactive control group (n =
28). The results showed that regular exercise increased cytotoxic
activity of natural killer cells. Other indirect effects of exercise
shown in human studies that might benefit patients with cancer
might be brought about by interaction with age-related
processes, such as immunosenescence and inflammaging. For
example, exercise training or remaining physically active
throughout life might prevent, limit, delay or even reverse
some aspects of immunosenescence (190, 299, 302). A
potential mechanism is limiting the expansion of late-stage
differentiated T cells by exercise mobilizing these cells to
peripheral tissues, where they are exposed to apoptotic signals,
followed by a mobilization of hematopoietic cells and trafficking
to the thymus, stimulating development of naïve T cells (190).
This hypothesis is supported by several observational studies,
including a comparison of 125 regular cyclists (55–79 years), 75
age-matched older adults and 55 young adults who did not
exercise regularly (303). Cyclists exhibited many features of a
less-aged immune system, including lower proportions of late-
stage differentiated T cells, high frequencies of B cells, lower
levels of IL-6, and higher levels of the thymoprotective cytokine
IL-7 (303). In support, another study has shown that higher
levels of directly measured cardiorespiratory fitness are
associated with lower frequencies of late-stage differentiated
T cells and higher frequencies of naïve T cells (304). Finally,
it is well established that regular exercise and physicalFrontiers in Immunology | www.frontiersin.org 19activity can counter inflammation, and perhaps over a lifetime,
this effect limits inflammaging (42, 299, 300). For example,
a study of 3075 participants aged 70–79 years reported lower
levels of inflammatory markers, including IL-6, TNF-alpha
and CRP, among those who performed higher levels of
exercise (305).
Adiposity Is Associated With Poor
Cancer Outcomes
Overweight and obesity are characterised by excess accumulation
of adipose tissue and are commonly been defined using Body
Mass Index (BMI), of between 25–30kg/m2 or more than 30kg/
m2 respectively (306). Being overweight or obese is associated
with an increased risk of developing breast cancer, and these
associations are strongest in postmenopausal women (307, 308).
However, a higher BMI and/or higher percentage body fat are
measurements that have also been associated with worse clinical
outcomes among women diagnosed with breast cancer,
including worse prognosis, higher risk of recurrence, and lower
overall and disease-specific survival (38–40). For example,
a metanalysis showed that there appears to be a linear
relationship between BMI and mortality beginning from 20 kg/
m2 when assessed before diagnosis and up to 12 months after
(40). Moreover, obesity also appears to have an impact on the
effectiveness of some treatments. A pooled study compared data
from 8 prospective trials of breast cancer patients treated with
neoadjuvant chemotherapy and found that high BMI negatively
influenced the response to anthracycline-taxane based treatment,
and was significantly associated with lower rates of pathological
complete response (309). High BMI was also associated with
shorter disease-free survival and overall survival independently
of pathological complete response in luminal-like tumors and in
triple negative breast cancer. In addition, obesity has been linked
to the development of tumor metastases (310) and recurrence
(311). For example, in a study of 1250 HER2 positive breast
cancer patients it was shown that in the ER negative subgroup of
patients, obese individuals were more likely to develop distant
metastases at 5 years (33.4%, 95% CI: 22.1–50.5) than those in
the overweight (17.9%, 95% CI: 12.3–25.9) or under/normal
weight (17.5%, 95% CI: 13.8–22.4) groups (310). However, not
all studies evaluating the influence of overweight and obesity in
cancer settings have reported worse outcomes compared to lean
counterparts: this phenomenon has been named the “obesity
paradox” as some studies reported that people with a high BMI
responded better to therapy than expected or had better survival
rates (312). As an example, a prospective study of 88 metastatic
breast cancer patients on palliative chemotherapy analyzed the
impact of BMI on survival and treatment response over a follow
up period of 40 months (313). It was shown that a greater
proportion of overweight patients were most responsive to
treatment (56%) followed by obese patients (30%) compared to
a smaller proportion in the normal weight group (15%) (313).
Moreover, patients with a BMI ≥25 kg/m2 survived for longer (19
months) in comparison with patients who had a BMI < 25 kg/m2.
However, it is worth considering that this study has a relatively
small sample size and it may not have adequately controlled forFebruary 2021 | Volume 11 | Article 616188
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receptor status, extent of disease, cardiovascular risk, etc.
Adiposity Could Be Associated With Poor
Cancer Outcomes Due to Undertreatment
It has been suggested that in the past, obesity has been linked
with undertreatment, where the dose of some chemotherapies
has been adjusted to the ideal body mass of a patient, or
arbitrarily capped at a body surface area of 2.0 m2. For
example, a retrospective cohort study compared treatment
patterns among overweight, obese, and patients of a normal
weight, in a total of 9672 breast cancer patients treated with
chemotherapy (314). The results showed that, compared to the
9% of people in the healthy weight group, 11% of the overweight
group, 20% of the obese group, and 37% of the severely obese
group, were administered dose reductions during their first
chemotherapy cycle. This reduction in the dose has been
associated with poorer outcomes (315), and could partially
explain why adiposity relates to worse prognosis. The rationale
for dosing chemotherapy based on body surface area, rather than
absolute body mass, is to avoid toxicity, however evidence
shows that this strategy could lead to poor clinical outcomes
and that toxicity is unlikely. For example, a study examined
data from 1,435 stage II breast cancer patients undergoing
adjuvant chemotherapy to determine if dosing based on
actual body mass increased risk of toxicity (316). Analyses
during the first chemotherapy cycle showed that patients
with a BMI ≥ 27.3 kg/m2 who were dosed according to actual
body mass did not exhibit excess toxicity (% of women with
toxicity: 47% of overweight women vs. 51% of lean women,
P = 0.51). Indeed, compared to overweight women who
received a dose reduction due to body surface area dosing,
overweight women who received their dose based on actual
body mass, had an adjusted risk ratio of treatment failure of
0.73 95% CI: 0.53–1.00, indicating that dose reduction can lead
to poor clinical outcomes. However, guidelines now advocate
dosing chemotherapy for obese patients based on absolute body
mass (317, 318). Thus, understanding why obesity is associated
with poor treatment outcomes, requires further investigation.
Adiposity Influences Cancer
Biomarker Profiles
Obesity is associated with particular molecular subtypes of breast
cancer. For example, a study evaluated the link between BMI and
breast cancer subtypes (319). In a retrospective analysis of 848
patients with primary operable breast cancer, groups were
formed on the basis of BMI: normal weight (BMI = 18–24.9
kg/m2), overweight (BMI = 25–29.9 kg/m2) and obese (BMI > 30
kg/m2). The results showed that triple negative breast cancer was
more common among overweight and obese women, whereas
HER2-positive tumors were more frequent among women of
normal weight.
Body composition can also affect the properties of tumors, as
well as the levels and characteristics of some cancer biomarkers.
Evidence in support comes from randomized and controlled
trials implementing behavioral or lifestyle interventions to bringFrontiers in Immunology | www.frontiersin.org 20about changes to physiology. For example, one study
randomized 32 overweight or obese stage 0-II breast cancer
patients into an intervention and control group as part of a 30
day pre-surgery “weight loss” study (320). The intervention
group received counseling on caloric restriction and aerobic
exercise to promote a change in body mass of 0.68–0.92 kg/
week. The control group received nutritional counseling and
upper body resistance exercise which was assumed to elicit a
smaller energy expenditure than aerobic exercise. Circulating
cytokines and metabolic measurements implicated in cancer
progression but also tumor characteristics were assessed. The
intervention group exhibited a greater change in body mass than
the control group (−3.62 vs. −0.52 kg) and exhibited greater
changes in metabolic measurements, including serum leptin and
fasting insulin, and inflammatory markers such as TNF-alpha.
Most importantly, a greater change to body mass and
accelerometer-measured physical activity was positively
associated with an infiltration of the CD56+dim cytotoxic
sub-population of natural killer cells into tumors. Indeed,
tumors from the intervention group were characterized by
a greater expression of key genes associated with immune
cell recruitment (e.g., CX3CL1, CXCL1, and CXCL12), and
higher TNF-alpha, but there were no differences in Ki-67
between groups.
Other evidence for body composition affecting cancer
biomarkers comes from cross-sectional studies. For example,
one study investigated the association between BMI in 535 post-
menopausal women with operable breast cancer and the
expression of HER2. The results showed that, with increasing
BMI, there was a significant decrease in HER2 overexpression
(321). The circulating form of HER2 has also been shown to be
positively associated with BMI in a healthy population of males
and females aged 45–65 years (322). Other cross-sectional
studies have examined the influence of BMI on results from
molecular profiling tests. For example, 865 postmenopausal
women with breast cancer were divided into groups on the
basis of BMI (<25 kg/m2, 25–30 kg/m2 or ≥30 kg/m2). It was
shown that IHC4 and Oncotype RS had the most prognostic
value for distant recurrences in the group with the lowest BMI
and there was no prognostic value in the group with a BMI ≥30
kg/m2. In the case of Prosigna, the score was most prognostic in
patients with a BMI 25–30 kg/m2. Other cross-sectional studies
have examined TILs in the context of body composition. For
example, functional tumor infiltrating CD8+TILs were assessed
in two groups of breast cancer patients who were classified as
either lean (BMI < 25 kg/m2) or obese (BMI > 32.5 kg/m2). It was
shown that CD8+ TILs from obese patients had a significantly
lower expression of Granzyme B (323). Furthermore, there was a
significantly lower number of these cells in the lymph nodes
draining the tumor in the obese group.
Other studies have examined soluble cancer biomarkers in a
variety of body fluids. For example, a study of 128 women with
breast cancer (89 post-menopausal) and 254 without breast
cancer (125 post-menopausal) measured prostate specific
antigen (PSA) in serum and nipple aspirate fluid (324). Among
women with breast cancer, PSA measured in nipple aspiratesFebruary 2021 | Volume 11 | Article 616188
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(r = −0.53, P = 0.049), whereas PSA correlated positively with
BMI in samples from post-menopausal women (r = 0.37, P =
0.017). Among women without breast cancer, serum PSA was
negatively correlated with BMI in both pre- (r = −0.56, P = 0.001)
and post-menopausal women (r = −0.37, P = 0.017), but this
association was lost when controlling for plasma volume (324).
Indeed, obesity is associated with an expansion of blood and
plasma volume (325–327) and it is often not considered that the
concentration of cancer biomarkers reported in cross-sectional
studies could be affected. For example, a study investigated the
effect of plasma hemodilution on the concentration of several
tumor markers in 6917 healthy women and found that BMI was
significantly positively associated with a greater plasma volume,
as well as with higher serum concentrations of CEA and a‐
fetoprotein and lower concentrations of CA 125 and CA 19.9
(328). Even in investigations examining changes over time with
serial measurements, results might be affected by shifts in plasma
volume. Bouts of exercise that could have been undertaken by
study participants and patients in the hours before blood
sampling, which is sometimes not controlled for, can decrease
plasma volume by up to about −10%, artificially increasing the
concentration of some measurements (329, 330). Although these
potential inaccuracies in reported values are probably only a
minor consideration, they could shift a measurement above or
below a cut-off or threshold that influences treatment decisions,
or with serial measurements, could give falsely influence
estimates of disease progression.Adiposity Can Affect Tumors Directly and
Indirectly
The mechanisms underlying links between obesity and breast
cancer treatment have not been determined. Some mechanisms
could be indirect and systemic due to the impact that overweight
and obesity has on metabolic health, inflammation, and immune
competency, whereas other mechanisms could be more direct, or
at least related to the characteristics of local tissue surrounding
breast tumors. Adipose tissue could in principle contribute to
local tumorigenesis, but perhaps counter-intuitively, women
with a high percentage of breast adipose tissue, are at a lower
risk of disease (331). Indeed, high mammographic density,
characterized by radiologically dense breasts consisting of
epithelial or stromal tissue which appears light on a
mammogram, compared to adipose tissue which appears dark,
is a strong predictor of breast cancer risk (332, 333). Although
BMI and physical activity should be considered when
interpreting mammographic density data (334, 335) it is
important to emphasise that the characteristics of breast
adipose tissue, such as the phenotype, and the secretory profile,
are probably the most important factors that could influence
breast tumors.
In vitro and in vivo animal studies have examined whether
interactions between breast cancer cells and different cell types
within surrounding adipose tissue, such as mature and immature
adipocytes, and normal and cancer associated fibroblasts,Frontiers in Immunology | www.frontiersin.org 21influence tumor progression (336, 337). Using cell co-cultures
and mouse models, it was shown that cancer cells triggered
phenotypical changes in the surrounding adipocytes, such as
increased production of proteases and pro-inflammatory
mediators including IL-6, IL-8, CCL2 and CCL5 (336). Indeed,
this cross-talk between so-called cancer-associated adipocytes,
contributed toward cancer progression and invasion (336).
Cytokine production was enhanced further when cancer cells
interacted with immature adipocytes stimulating mammosphere
formation, resulting in higher invasion and metastatic potential.
Indeed, when the cancer cells were injected into mice after
co-culture with immature adipocytes for 7 days, the number
of tumor initiating cells increased 3-fold, and the volume of
metastases in the lungs increased as did the number of
circulating tumor cells (337). Further experiments showed that
immature adipocytes and the release of cytokines upregulated
embryonic stem cell transcription factors c-MYC, SOX2, and
NANOG, through Src activation, promoting the expansion of
cancer stem cells (337).
Other animal studies have shown that adipocytes from
human and mouse breast tissue recruit and activate
macrophages (338). For example, one study has used a human-
in-mouse breast cancer model whereby human breast adipose
stromal cells, modified to model an inflammatory environment
of obese breast, are injected into the mouse mammary fat. In
this work, mice were randomized to eat either a normal
diet (ND) or to eat a diet with increased calories from fat
(HFD). It was shown that in mammary glands of HFD mice,
total numbers of macrophages were significantly increased
(4.4 x105 ± 0.5 x 105; macrophages/gland) compared with ND
mice (2.5 x105 tumor± 0.5 x105; P = 0.05). It was also shown
that the recruitment and activation of these macrophages
was through the CCL2/IL-1b/CXCL12 signaling pathway.
These findings provide a mechanistic role for adipocytes
leading to adipose tissue dysfunction in breast tissue, which
could precede tumor development (338). A study in mice
evaluating obesity-promoted breast tumor growth showed
that increased oxidation of fatty acids and reduced glycolysis,
both enhanced by the leptin-PD-1-STAT3 axis in CD8+
TILs, promoted obesity-related breast tumorigenesis and
contributed to resistance to immunotherapy (323). Inhibiting
STAT3 or fatty acid oxidation restored CD8+ T cell effector
functions and inhibited tumor development in obese mice.
Other murine studies have provided further evidence that
obesity can impair cancer immune surveillance. For example,
showing that obesity promotes hyperactivation of CD8+ TILs,
and an accumulation of granulocytic myeloid-derived suppressor
cells (G-MDCSs), which induced Fas/FasL mediated apoptosis
of CD8+ T (339).
Research in humans has also examined links between
breast cancer and dysfunctional adipose tissue. For example,
one study compared two groups of individuals without
a breast cancer diagnosis (lean n = 37, obese n = 19) to
patients with breast cancer (n = 12) (340). Using RT-PCR to
examine expression levels of genes in circulating leukocytes, it
was shown that TNF-alpha, IL-6, leptin and ErbB2, wereFebruary 2021 | Volume 11 | Article 616188
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diagnosis and among breast cancer patients compared to the
lean group. Assuming leukocyte gene expression of ErbB2 is
representative of gene expression in breast tissue, then obesity-
associated over-expression could have important implications
for tumorigenesis and treatment, given its role in metastatic
disease. A possible mechanism underlying interactions between
disease progression and adipose tissue surrounding breast
tumors could be the adoption of an adipose derived secretory
phenotype that attracts different populations of immune cells.
Adipose tissue dysfunction is characterised by changes to the
tissue microenvironment at cellular and structural levels, which
results in abnormal secretions derived from adipocytes and local
immune cells (197). Changes include adipocyte hypertrophy,
hypoperfusion, hypoxia and impaired insulin signaling, leading
to an enlargement of adipose tissue, low-grade systemic
inflammation due to the release of inflammatory cytokines
(341, 342) and possibly exacerbated immunosenescence (343).
These changes lead to immune cell accumulation within adipose
tissue, most prominently consisting of macrophages with a pro-
inflammatory phenotype and effector-memory CD8+ T cells
(195, 197). The implications of attracting highly inflammatory
populations of immune cells to areas surrounding breast tumors
are unknown, but could conceivably have both negative and
positive effects, depending on the cell type recruited, perhaps in
part providing one explanation for the “obesity paradox”. For
example, a study investigated 334 breast tumors from patients
with long-term follow-up and showed that high frequencies of
tumor infiltrating CD8+ T cells were associated with higher
cumulative breast cancer specific survival (344). On the other
hand, a metanalysis of sixteen studies and a total of 4,541 breast
cancer patients showed that overall survival and disease free
survival correlated with high frequencies of tumor associated
macrophages (overall survival: HR = 1.50, 95% CI: 1.20–1.88 vs.
disease free survival: HR 2.23, 95% CI: 1.72–2.90) (345).
Although in obesity, there is often a large accumulation of
abdominal adipose tissue, deposition occurs elsewhere, including
the breast, and a question that remains is whether regional
depots of adipose tissue interact differently with tumors. To
further improve our understanding of this question, a study
isolated breast tissue-derived and abdominal tissue-derived
mesenchymal stem cells (MSCs) from healthy adults
undergoing cosmetic surgery (346). MSCs, with the capacity to
differentiate into adipocytes, were co-cultured with MCF7 or
MDA-MB-231 breast cancer cell lines and compared to co-
culture with human macrophages. MSCs from both regions
stimulated proliferation of the breast cancer cell lines similarly,
and abdominal MSCs had a higher expression of IL-1-beta
compared to breast MSCs. Co-culturing MSCs with
macrophages led to higher levels of VEGF-A, VEGF-C, SER-
PINE1, FGF2, IL-1-beta and IL-6 gene expression in
macrophages. Thus, MSCs, and perhaps adipocytes from both
breast and abdominal depots, interact with macrophages, which
could lead to the development of dysfunctional adipose tissue.
In summary, further studies are required to understand
mechanistic interactions between adipose tissue—includingFrontiers in Immunology | www.frontiersin.org 22adipocytes and adipose-associated immune cells—with breast
cancer cells. Indeed, if the dysfunction of adipose tissue
surrounding breast tumors influences the accumulation of local
immune cells, tumor infiltrating lymphocytes, and other tumor
characteristics, then this process could have an impact on the
expression of tumor biomarkers and cancer progression.
Moreover, systemic adipose tissue dysfunction could lead to
metabolic, inflammatory and immunological profiles that have
been associated with poor clinical outcomes. Encouragingly, if
adipose tissue dysfunction and adipose derived secretions
contribute to tumorigenesis, then lifestyle interventions could
in principle limit disease progression and facilitate treatment. For
example, regular exercise, triggers a reduction in fat mass and
limits the release of adipokines, resulting in anti-inflammatory
adaptations (42, 299, 347).CONCLUSIONS
Managing heterogeneity in the clinical response exhibited
by patients remains a challenge. The first part of this
article summarized biomarkers that are available to address
this problem, by informing therapeutic options, assessing
pathological response and predicting clinical outcomes. The
second part of this article summarized factors such as aging,
physical activity, and body composition, that might influence
the sensitivity and specificity of these biomarkers, by
modulating the cellular composition and function of tissues.
This article has highlighted that the characteristics of patients,
including their age, physical activity level and adiposity,
could interact with disease progression and influence
treatment effectiveness due to a combination of direct and
indirect mechanisms (Figure 1). Indeed, processes and
profiles associated with lifestyle, including metabolic health,
inflammaging and immunosenescence, are gaining increasing
recognition as being important factors that can influence cancer
and its treatment. The positive outlook is that some of these
processes might be reversible, or at least, their development
might be slowed or limited, by for example, encouraging
patients to lead a physically active lifestyle, at almost any
stage of disease. In summary, the measurement of cancer
biomarkers in blood or in tumors could be influenced by
patient characteristics and their lifestyle, because these factors
affect the composition and function of cells and tissues across
the body and across the life-course. These factors are not
commonly considered clinically or in research, either for
practical reasons or because the supporting evidence base is
developing. Thus, a broader perspective within cancer care is
required which integrates objective measurements of aging,
lifestyle and other patient characteristics, using a combination
of established biomarkers measured in tissues and in blood,
but also broader whole-body measurements of physical
functioning and frailty (216, 219, 220). Given the literature
presented herein, we hope that this article encourages an
interdisciplinary phenomic approach in oncology research
and clinical management.February 2021 | Volume 11 | Article 616188
Arana Echarri et al. Aging, Lifestyle and Breast CancerFIGURE 1 | Breast cancer prognosis, tumor properties, and clinical outcomes can be influenced by the characteristics of patients, including: age, body composition
and adiposity, or exercise and physical activity. References are considered to be representative examples of robust human studies with breast cancer patients.
(A) Cancer biomarkers can be assessed in tumor tissue or in blood and can provide information about prognosis and the clinical response to different treatments.
(B) Some studies have shown that older age is associated with lower expression of tumor proliferative markers (e.g., Ki-67) and proteins implicated in tumor
progression (e.g., P53), and higher expression of certain hormone receptors (e.g., ER, PR). (C) Higher adiposity has been associated with a lower expression of
HER2, a lower magnitude of tumor immune cell infiltration and lower activation status of tumor-resident CD8+ T cells. (D) Bouts of exercise and physical activity have
been shown to decrease some inflammatory markers (e.g., IL-2) and increase pro-angiogenic factors (e.g., PLGF and EPCs expressing VEGFR-2). Higher tumor
vascularity could facilitate the delivery of drugs to a tumor. (E) The effectiveness of breast cancer treatments can be influenced by tumor properties [shown in panel
A] and the characteristics of patients [shown in (B–D)]. (F) In turn, interaction between tumor properties, the characteristics of patients, and the effectiveness of
breast cancer treatments can influence clinical outcomes. EPCs: Epithelial Progenitor cells, ER: Estrogen Receptor, HER2: Human Epidermal Growth Factor
Receptor-2, IL-2: Interleukin 2, IL-6: Interleukin 6, KI-67: nuclear protein Ki-67, PGLF: Placenta Growth Factor, PR: Progesterone Receptor, P53: tumor protein 53,
TILs: tumor Infiltrating Lymphocytes, VEGFR-2: Vascular Endothelial Growth Factor Receptor-2. Figure created with BioRender.com. Adapted from “tumor
Microenvironment 2” and “Types of Cancer Treatment”, by BioRender.com (2020). Retrieved from https://app.biorender.com/biorender-templates.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 61618823
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